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The urea cycle converts ammonia, the toxic byproduct of protein metabolism, to 
non-toxic urea utilizing six enzymes in mammalian liver hepatocytes. In the 
mitochondria, the enzyme N-acetylglutamate synthase (NAGS), produces the essential 
allosteric activator, N-acetylglutamate (NAG), for the first enzyme of the cycle, 
carbamylphosphate synthetase 1 (CPS1). Ammonia sequestered by CPS1 is condensed 
with bicarbonate and phosphate from ATP to produce to carbamylphosphate, which is 
then condensed with ornithine to produce citrulline by ornithine transcarbamylase 
(OTC). Citrulline is then transported to the cytoplasm where it is further converted by 
the distal urea cycle enzymes argininosuccinate synthetase, argininosuccinate lyase, and 
arginase 1 to the end product, urea.  
Prior to sequestration of ammonia, signaling pathways sense dietary protein load. 
Analysis was conducted to determine the effect of protein composition on metabolic 
signaling and nutrient sensing pathways AMPK, mTOR, and eIF2, promote 
  
transcriptional activation of urea cycle genes and translation of urea cycle proteins. 
Future studies will determine the importance of these pathways on the urea cycle and 
whether post-translational control mechanisms, such as phosphorylation, also respond to 
protein in the diet.  
Since NAGS plays an important role in controlling the rate of urea production by 
activating the rate limiting CPS1, its regulatory mechanisms control ureagenesis flux. 
This project elucidated the regulatory domains of NAGS including a promoter which 
contains multiple tissue- and species- specific transcription initiation sites and binding 
sites for transcription factors CREB and Sp1. It also found and characterized an 
enhancer 3kb upstream of the translational start site which confers liver specificity and 
has binding sites for NF-Y and HNF-1. These transcription factors are regulated by 
glucocorticoid and glucagon hormone signaling pathways and are also regulated in a 
tissue selective manner.  
A deficiency of NAGS in humans and mice leads to high ammonia, low urea, and 
high glutamine levels in the plasma, and can be overcome by treatment with N-
carbamylglutamate (NCG). This project identified a patient with NAGS deficiency and 
hyperammonemia caused by a deleterious mutation in the HNF-1 binding site within the 
enhancer of the NAGS gene, which was identified and characterized by this research. 
This mutation caused decreased transcription of NAGS due to reduced HNF-1 binding. 
Subsequently, this work found disease-causing mutations in the promoter region of OTC 
which have been shown to interfere with HNF-4 binding.  
The knowledge garnered by this project significantly increases our understanding 
of the regulation of urea cycle RNA and protein expression and their role in disease 
  
pathophysiology. Understanding of these mechanisms will lead to improved diagnoses 
and continued development of effective treatments for people with urea cycle disorders 
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Chapter 1: Introduction 
Urea Cycle Function and Regulation 
The urea cycle, discovered by Hans Krebs and Kurt Henseleit in 1932 [1], is 
essential for the protection of the central nervous system from the toxic effects of 
ammonia. Accumulate ammonia in the blood can cause lethargy, coma and death and can 
lead to permanent brain damage and intellectual and developmental disabilities. As the 
by-product of protein catabolism, ammonia is converted to non-toxic urea in mammalian 
liver hepatocytes through six enzymes and two mitochondrial membrane transporters. 
One of the enzymes, N-acetylglutamate synthase (NAGS), is found in the mitochondria 
of liver hepatocytes and small intestine epithelial cells. NAGS catalyzes the formation of 
N-acetylglutamate (NAG) from glutamate and acetyl CoA, producing the obligatory 
cofactor (NAG) for the first enzyme of the urea cycle, carbamylphosphate synthase 1 
(CPS1). Following the binding of NAG, mitochondrial CPS1 sequesters ammonia, the 
first of two waste nitrogen molecules destined to make urea. Ammonia, bicarbonate and 
phosphate from ATP are condensed by CPS1 into carbamyl phosphate. The next enzyme 
in the cycle, ornithine transcarbamylase (OTC), forms citrulline from carbamyl phosphate 
and ornithine in the mitochondria.  Aspartate, the source of the second waste nitrogen, 
and citrulline are then transported out of the mitochondria to the cytosol by the ornithine 
transporter (ORNT) and citrin, respectively. In the cytoplasm, the next enzyme, 
argininosuccinate synthase (ASS), condenses citrulline and aspartate to produce 
argininosuccinate. Argininosuccinate lyase then converts argininosuccinate to arginine 
and fumarate, arginine is then broken down by Arginase 1 (ARG1) to urea and ornithine. 
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Urea is excreted from the body through the kidneys and ornithine is transported back into 
the mitochondria by the ornithine transporter to be reused by the urea cycle (Figure 1).   
In 1939, one of the earliest studies on metabolic adaptations to diet examined urea 
cycle enzyme activity and showed that arginase activity changed in response to diet [2]. 
Since then, studies have shown that urea production is regulated by dietary protein intake 
such that it increases following consumption of a high protein diet, decreases following 
consumption of a low protein diet, and increases during acute starvation due to increased 
muscle catabolism and production of endogenous nitrogen waste. This mechanism 
regulates the activity of CPS1, OTC, ASS, ASL and ARG1 [3,4,5] by controlling the rate 
of enzyme synthesis [6,7]. Early studies did not examine the regulation of NAGS as it is 
of very low abundance and is difficult to assay [8]. Later studies, in 1977, examined the 
regulation of NAGS activity and found that its activity also increases in response to diet 
[9].  
Precursrs and metabolites of the urea cycle have been shown to regulate activity 
of the individual enzymes.  In addition to dietary protein, NAGS activity is increased by 
arginine, ammonia, and glutamate [10,11,12]. Activity of CPS1 is completely dependent 
on the availability of NAG and is stimulated by ammonia and ornithine [13,14,15,16]. 
OTC activity is dependent on the abundance of its substrate, carbamyl phosphate, and is 
inhibited by an excess of citrulline [13,14,17]. ASS activity is dependent on the 
abundance of citrulline and is stimulated by ammonia as well as aspartate [7,14,18].  
Finally, the abundance of arginine mediates repression of ASS and ASL and limits the 





Figure 1. The urea cycle.  
The urea cycle system converts waste nitrogen from ammonia and aspartate to urea using 
six enzymes (blue) and two transporters (in circles) in the mammalian liver.  
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Short-term regulation of urea production is most likely based on both substrate 
availability and post-translational processing of urea cycle enzymes considering their 
capacity for ureagenesis exceeds the physiological rate of urea production [19]. CPS1 is 
the rate-limiting enzyme for short-term ureagenesis and its activity is directly related to 
the production of its allosteric activator, NAG [12,20]. Early studies of ureagenesis failed 
to show a short-term increase in NAGS activity in response to increased amino acid load 
and suggested, instead, that the increased production of NAG was due to an increase in 
hepatic glutamate [12,21]. While glutamate substrate load may be a major regulator of 
NAG production, it seems unlikely that regulation of the complex interactions required to 
maintain nitrogen homeostasis are dependent only on substrate concentration [22], but in 
addition may involve a combination of amino acid sensing to stimulate gene transcription  
[23] and post-translation processing of urea cycle proteins [24,25,26,27,28,29]. 
Amino Acid Sensing 
Hepatic metabolism of fats, carbohydrates, and proteins is kept in balance by 
complex interactions between the regulatory networks that sense nutrients and the 
pathways that utilize them. These nutrient sensing pathways include: 1. the adenosine 5’-
monophosphate-activated protein kinase (AMPK) pathway, which acts as an intracellular 
energy sensor [30,31], 2. the mammalian target of rapamycin (mTOR) pathway, which 
stimulates translation [32], and 3. the eukaryotic initiation factor 2 (eIF2)/general control 
nondepressible kinase 2 (GCN2) pathway, which inhibits translation upon sensing of 
amino acid deprivation [32,33,34]. The mechanisms that allow hepatocytes to adapt to 
changes in dietary carbohydrate and protein composition are in part signaled by amino 
acids [23,35]. As such, in cultured primary hepatocytes, phosphorylation of AMPK, 
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GCN2, and the downstream target of GCN2, eukaryotic initiation factor 2α (eIF2α), 
decreased [23] while phosphorylation of mTOR and the downstream targets of the mTOR 
kinase, eukaryotic initiation factor 4E-binding protein-1 (eIF4E-BP1) and p70 S6 kinase 
(p70S6K) increased in response to a high protein diet and particularly leucine [23,36]. 
Targeted manipulation of these pathways by rapamycin, inhibitor of mTOR [35,37], and 
5-aminoimidazole-4-carboxamide riboside (AICAR), activator of AMPK [38,39,40], can 
be used to discern the role these pathways play in expression of urea cycle genes and 





Figure 2. Signaling pathways involved in nutrient sensing. 
The AMPK, mTOR, and eIF2 pathways regulate transcription and translation in response 
to signals from the diet.  
 
 7 
Transcriptional Regulation of Urea Cycle Genes 
Regulation of the urea cycle genes is mediated, at least in part, by hormones and 
dietary amino acid concentration. In general, glucocorticoids increase enzyme activity, 
and glucagon, or analogs of its second messenger, cAMP, increase mRNA levels in 
response to fasting [41].  The mechanisms for transcriptional regulation are not fully 
understood, but previous studies of the promoter and enhancer regions of CPS1, OTC, 
ASS, ASL, and ARG1 have identified sites where hormone responsive transcription factors 
may bind and differentially regulate these genes. Table 1 lists the transcription factors 
shown to bind to these sites and regulate each gene’s expression. The DNA sequence of 
NAGS was identified in 2002 by Caldovic, et al. [42,43] and our elucidation of the 
transcriptional regulation of NAGS has recently been published [44] and is presented in 
chapter 2. In summary, the promoter of NAGS has binding sites for cyclic AMP 
responsive element binding protein (CREB) and multiple specificity protein 1 (Sp1) sites, 
whereas hepatic nuclear factor 1 (HNF-1) and nuclear factor Y (NF-Y) bind to the 
upstream enhancer. A naturally occurring mutation of the HNF-1 binding site in the 
NAGS enhancer of a patient with NAGS deficiency resulted in the inhibition of 
transcription factor binding and decreased transcription of NAGS [44]. Transcription of 
CPS1 is activated by TATA-binding protein (TBP).  The proximal and distal enhancers 
of the CPS1 gene contain binding sites for glucocorticoid response units including 
CCAAT-enhancer binding protein (C/EBP), activator protein-1 (AP-1), glucocorticoid 
receptor (GR), CREB, and tissue selective factor binding sites for hepatic nuclear factor 3 
(HNF-3) [45,46,47]. The OTC gene is expressed in a tissue specific manner such that 
activation of part of the promoter induces intestinal expression [48,49] while activation of 
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the enhancer induces liver expression [50,51,52]. The promoter contains binding sites for 
the liver selective hepatic nuclear factor 4 (HNF-4) [53,54] and repressor chicken 
ovalbumin upstream promoter-transcription factor (COUP-TF) [51,55]. The enhancer 
requires two transcription factors, HNF-4 and the glucocorticoid response factor C/EBP, 
for regulation of TBP activated transcription [47]. Study of the regulation of ASS, has 
identified multiple Sp1 binding sites in the promoter, which have been shown to 
cooperatively activate transcription; multiple Sp1 binding sites have been identified on 
the promoters of ASL and ARG1 as well [56,57]. ASS is also regulated through cAMP-
dependent phosphorylation of CREB [18,58] and AP-2 may play a role in the arginine-
mediated repression of this gene [59]. Within the promoter of ASL, Sp1 activates 
transcription, but it is unknown whether the binding of nuclear factor Y (NF-Y) acts to 
activate or repress transcription [60,61,62]. Sp1 and nuclear factor 1 (NF-1)/CCAAT-
binding transcription factor (CTF), both of which recognize the same region of DNA and 
bind in a mutually exclusive manner, can activate ARG1 transcription [63]. An enhancer 
of ARG1 resides approximately 11kb downstream of the translational start site, within 
intron 7, where two C/EBP factors bind along with two unidentified proteins to confer 




Table 1. Transcription factors that regulate urea cycle genes. 
 
Transcription Factors Gene Transcription Activators Proximal Enhancer Distal enhancer 
NAGS Sp1 CREB, FXR HNF-1, NF-Y 
CPS1 TBP C/EBP CREB, C/EBP, GR, HNF-3, AP-1, P1-3 
OTC TBP HNF-4, COUP-TF C/EBP, HNF-4/COUP-TF 
ASS Sp1 AP-2 CREB 
ASL Sp1 NF-Y   




As mentioned in the previous section, the nutrient sensors’ (mTOR, AMPK, and 
eIF2) phosphorylation state changes in response to dietary amino acid intake. One of the 
downstream targets of mTOR and AMPK, peroxisome proliferator-activated receptor 
gamma co-activator (PGC-1α) [65,66,67], regulates the expression of HNF-4 and GR 
[68,69], which in turn directly regulate the expression of OTC and CPS1 
[55,70,71,72,73]. Additional transcription factors, including C/EBP and CREB, require 
phosphorylation by the AMPK pathway members [74,75] to activate transcription of 
NAGS, CPS1, OTC, ASS, and ARG1 [47,63,73,76,77]. While HNF-1, regulator of NAGS, 
and HNF-3, regulator of CPS1, are not direct downstream targets of these pathways, 
HNF-1, -3, -4, and -6 regulate each other via complex feedback mechanisms. While 
HNF-6 does not bind to the regulatory regions of urea cycle genes, it binds to the 
promoter of HNF-4 [53,78] and simple feedback loops exist between HNF-1 and HNF-4 
[79,80,81] and between HNF-3 and HNF-6 [82,83]. In addition, many genes involved in 
hepatocyte metabolism exhibit multi-input regulation by a combination of two or more of 
the HNFs and synergistic activation through their interactions [53,81]. 
Hormone Signaling 
Many of the transcription factors described in the previous section are in part 
regulated by hormones. In fact, studies by Morris et. al, in the 1980s and 1990s, showed 
that transcription of CPS1, OTC, ASS, ASL and ARG1 was coordinately regulated in 
response to cAMP, glucocorticoids, and insulin [19,47,84]. Glucocorticoids increase 
enzyme activity of the urea cycle enzymes, and while they have little effect on the gene 
expression of OTC, transcription rates of CPS1 and ASL are stimulated by 
glucocorticoids in hepatocytes [41,85]. Recently, a transcriptional profiling study was 
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conducted in rats to examine the stimulatory effect of the glucocorticoid analog 
methylprednisolone on the urea cycle genes [86].  The authors concluded that 
glucocorticoid regulation of mRNA expression differs between urea cycle enzymes.  
CPS1, OTC, and ARG1 exhibit an acute response while ASS and ASL have a delayed 
response to glucocorticoids [86].  This difference in response may be explained by the 
glucocorticoid ability to stimulate or inhibit gene expression based on the regulatory 
proteins and transcription factors that are already present on the DNA control regions 
[86]. 
Transcription of CPS1, ASS, and ASL is rapidly stimulated by glucagon and 
cAMP analogs in rat liver [85] while transcription of OTC fails to be stimulated on a 
short-term time scale but is induced following 48 hour incubation with glucagon 
[41,84,87]. While the glucocorticoid response mechanism is still unknown and most 
likely mediated by proteins that are synthesized in response to the hormone [41], cAMP 
stimulation of mRNA expression does not require ongoing protein synthesis in rat 
hepatocytes [41]. Following short-term fasting or feeding of a low protein diet in vivo, an 
increase in glucagon activates the cAMP pathway and stimulates CREB phosphorylation 
by protein kinase A (PKA1) [88]. This results in diffusion of phosphorylated CREB into 
the nucleus and increased transcriptional activation of genes with CREB binding sites 
[89,90]. This mechanism may in part regulate cAMP stimulation of the urea cycle 
enzymes with known CREB binding sites, namely NAGS, CPS1 and ASS [46,76]. A 
combination of glucocorticoids and cAMP analogs produced large increases in 
transcription rates for all of the urea cycle enzymes except OTC in rats [85].  
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Expression of the urea cycle genes is differentially regulated in response to 
treatment with insulin and amino acids [21]. No significant difference in urea production 
was noted when hepatocytes were treated with high or low insulin alone when no 
additional source of nitrogen was presented to the cells. However, treatment with low 
levels of insulin in the presence of amino acids optimized hepatocellular function and 
increased urea synthesis due to increased expression of urea cycle enzymes while high 
levels of insulin and amino acids decreases enzyme expression [21]. In contrast to the 
noted induction of urea cycle enzyme expression by glucagon and cAMP, insulin has 
been shown to play an inhibitory role on expression of urea cycle genes in hepatocytes. 
[21,85]. Thus, urea cycle genes are differentially regulated in response to hormone 
signaling and each of the urea cycle enzymes may be subject to a combination of 
glucocorticoid, cAMP/glucagon, and insulin signaling.  
N-Acetylglutamate Synthase Deficiency 
A deficiency of any of the cycle enzymes can lead to a urea cycle disorder (UCD) 
manifested clinically as hyperammonemia. NAGS deficiency (NAGSD) (OMIM 237310) 
can result in the reduction or absence of NAG causing reduced or absent CPS1 activity. 
The resulting hyperammonaemia can cause vomiting, seizures, mental retardation, coma, 
and possibly death [91,92,93]. The phenotype of NAGSD is indistinguishable from CPS1 
deficiency (CPS1D) based on the clinical symptoms described above, and biochemical 
features include elevated plasma ammonia and glutamine and reduced urea and citrulline 
levels [94]. Since the enzymatic diagnosis of NAGSD requires an open liver biopsy and 
the assay can be inaccurate, this disorder is best diagnosed by sequencing of the coding 
and non-coding regions of the gene [95]. The first suspected case of NAGSD was 
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described in 1981 [96]. Several patients had been reported subsequently, but their 
diagnosis could not be confirmed until the NAGS DNA sequence was identified in our 
laboratory.  To date, twenty-two disease causing mutations in the NAGS coding sequence 
or intron/exon boundries [94] and one disease causing mutation in the enhancer region of 
NAGS [95] have been reported. The severity of this autosomal recessive disease seems to 
depend on the genotype. Patients with nonsense or frameshift mutations that lead to 
absence of the NAGS protein present in the neonatal period [97,98,99] while patients 
with hypomorphic alleles such as missense mutations that allow for some residual NAGS 
enzyme activity typically present after the neonatal period [95,100,101,102,103,104,105] 
and sometimes during adulthood (late onset) [93,106,107].  
During the first clinical presentation of any UCD, the initial focus of treatment is 
to lower plasma ammonia [108] by using scavenging agents such as sodium benzoate, 
sodium phenylacetate, or sodium phenylbutyrate [109], antibiotics to reduce nitrogen-
producing gut bacterial load, and dialysis to acutely remove excess ammonia [110,111]. 
N-carbamylglutamate synthase (NCG), a non-hydrolyzed glutamic acid derivative [112] 
that can activate CPS1 [96] in place of NAGS, is the only specific treatment for any UCD 
and it effectively restores ureagenesis and reverses the hyperammonemia in NAGSD. 
Administration of NCG during acute hyperammonemia crisis has rescued patients 
[113,114] and long-term treatment with NCG completely corrects the urea cycle block 
such that patients may consume liberalized dietary protein [114,115,116] without 
additional ammonia scavenging agents [98,102,113,114,117,118]. Currently, NCG is the 
only drug, for treatment of a UCD, in which the disease-causing enzyme can be by-
passed and the remaining urea cycle enzymes can carry on their normal function.  
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Ornithine Transcarbamylase Deficiency  
In contrast to the low prevalence of NAGSD, OTC deficiency (OTCD) (OMIM 
311250) is the most commonly occurring UCD with an estimated frequency of 1 in 
14,000 [91,119] due to location of the OTC gene on the X chromosome. When OTC is 
defective or absent, citrulline formation from carbamylphosphate and ornithine, is 
disrupted and results in increased concentrations of plasma ammonia, glutamine, alanine, 
urinary orotic acid and orotidine and decreased urea and citrulline. Conclusive diagnosis 
of OTCD consists of mutation analysis and/or liver biopsy to measure enzyme activity 
[120]. Because OTCD is x-linked, most of the patients are hemizygous males; when OTC 
activity is completely absent they present in the neonatal period and exhibit the most 
severe symptoms of vomiting, hyperammonemia and coma within the first few days of 
life [121,122,123]. Late-onset male patients and female heterozygotes, however, vary in 
disease severity and presentation of symptoms may occur from infancy to adulthood, or 
the disease may go unrecognized entirely [120,124,125,126]. The disease most often 
manifests in previously asymptomatic patients due to infection, injury, childbirth and 
other physiological stresses [127]. In general, patients with neonatal onset of disease 
exhibit mutations that abolish enzyme activity while late-onset patients have partial 
activity caused by mutations that destabilize OTC or affect the substrate binding sites 
[128]. 
The long-term treatment of OTCD includes a low protein diet with sodium 
benzoate or sodium phenylbutyrate as ammonia scavenging agents. If the severity of the 
disease is such that life-threatening symptoms  are expected to occur despite treatment 
[38,39,40], liver transplantation is currently the only option for a cure. As a prevention 
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for hyperammonemic episodes due to complete OTCD, liver transplantation provides the 
best opportunity for these patients to develop normally [129]. Due to limitations 
associated with liver transplantation including availability of donor livers, dangers of the 
procedure, and the necessary immunosuppressive drugs, gene therapy is currently being 
evaluated as an alternative treatment. Therapy with adeno-associated virus 8 (AAV8) has 
led to successful transgene expression in mice, dogs, and non-human primates 
[130,131,132,133] and has shown to restore activity of the human OTC enzyme in mice 
[134].  
In summary, the combined body of knowledge on urea cycle regulation at the 
mRNA and protein level spans from the dietary protein that triggers increased gene 
expression and phosphorylation of nutrient sensing pathway members to downstream 
targets of these pathways that act as the transcriptional regulators of the urea cycle genes. 
The contributions of the body of research contained within this dissertation substantially 
increases knowledge of the pathways involved in amino acid signaling and the role 
nutrient sensing plays in transcriptional regulation of the urea cycle genes, describes 
transcriptional regulation of NAGS, enables mutation identification in gene transcription 
regulatory regions and subsequent diagnosis of OTCD and NAGSD, and has led to 
treatment with markedly improved long-term outlook of NAGSD.  
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Chapter 2: Transcriptional Regulation of N-Acetylglutamate 
Synthase 
Publication 
Sandra Kirsch Heibel, Giselle Yvette Lopez, Maria Panglao, Sonal Sodha, 
Leonardo Mariño-Ramírez, Mendel Tuchman, Ljubica Caldovic. (2012) Transcriptional 




Ammonia, the toxic product of protein catabolism, is converted to urea by the 
urea cycle in the liver of mammals.  Incorporation of two nitrogen atoms into urea is 
catalyzed by six enzymes: three of them mitochondrial, N-acetylglutamate synthase 
(NAGS; EC 2.3.1.1), carbamylphosphate synthetase 1 (CPS1; EC 6.4.3.16) and ornithine 
transcarbamylase (OTC; EC 2.1.3.3), and the other three cytosolic, argininosuccinate 
synthetase (ASS; EC 6.3.4.5), argininosuccinate lyase (ASL; EC 4.3.2.1) and arginase 1 
(Arg1; EC 3.5.3.1).   
NAGS catalyzes the formation of N-acetylglutamate (NAG), an essential 
allosteric activator of CPS1, in the mitochondrial matrix of hepatocytes and small 
intestine epithelial cells [42,43]. Within hepatocytes, NAGS activity and NAG abundance 
are regulated by L-arginine, ammonia, and dietary protein intake [4,8,10] and therefore, 
the NAGS/NAG system may play a critical role in the regulation of ureagenesis in 
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response to these factors [11]. While studies in the 1980s and 1990s identified the cis-
acting motifs regulating transcription of the urea cycle enzymes CPS1 [77,135,136,137], 
OTC [50,51,55,73], ASS [57,76,138], ASL [61,62,139], and ARG1 [63,140], the 
mammalian NAGS gene was not identified until 2002 [43] and we can now report for the 
first time on its transcriptional regulation.   
Many studies have identified regulatory links between the urea cycle genes and 
glucocorticoids and glucagon [19,47,84], however the mechanism of regulation differs 
for each gene [3,41,84,141,142]. Transcription of CPS1 is activated by TATA-binding 
protein (TBP) while its proximal and distal enhancers contain binding sites for 
glucocorticoids and cAMP responsive factors including CCAAT-enhancer binding 
protein (C/EBP), activator protein-1 (AP-1), glucocorticoid receptor (GR) and cAMP 
response element binding (CREB). Sites for binding tissue selective factors including 
hepatic nuclear factor 3 (HNF-3) are also present [45,46,47].  Tissue specific expression 
of the OTC gene is induced in the intestine and liver by HNF-4, which binds in the 
promoter [51,73,143] while binding of both HNF-4 and C/EBP to the enhancer, induces 
high expression levels in the liver [47,50,51,52,73].  ASS transcription is regulated by 
cooperative binding of multiple copies of specificity protein 1 (Sp1) [57]. ASL is 
regulated through Sp1 and the positive regulator, nuclear factor Y (NF-Y), which binds 
within the promoter of ASL to activate its transcription [60,61,62,139]. Sp1 and nuclear 
factor 1 (NF-1)/CCAAT-binding transcription factor (CTF) activate ARG1 transcription 
while two C/EBP factors and two unidentified proteins bind within an enhancer in intron 
7 to confer glucocorticoid responsiveness [63]. 
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Abundance of urea cycle enzymes correlates with dietary protein intake [3,4]. 
Transcription of urea cycle genes is in part regulated by the glucocorticoid and glucagon 
signaling pathways [142,144]. Therefore, we postulate that there exists a nitrogen sensing 
mechanism that is both responsive to amino acid(s) and hormone stimulation and that an 
understanding of the transcriptional regulation of NAGS could contribute to the 
understanding of such mechanism.  
In this study, we identified two regulatory regions upstream of the NAGS 
translation start site that contain highly conserved protein-binding DNA motifs. We 
subsequently confirmed that these regions function as promoter and enhancer and that the 
enhancer is most effective in liver cells. Avidin-agarose protein-DNA pull-down assays 
have been used to confirm binding of Sp1 and CREB within the NAGS promoter and 
Hepatic Nuclear Factor 1 (HNF-1) and NF-Y within the enhancer regions. Chromatin 
Immunoprecipitation (ChIP) and quantitative real-time PCR have been used to 
independently verify that Sp1 and CREB bind to the promoter region and HNF-1 and NF-
Y bind to the enhancer region. We also used 5’RACE analysis to identify multiple 
transcription start sites for NAGS that may be species and tissue specific. These findings 
provide new information on the regulation of the NAGS gene, and suggest possible 
mechanisms for coordinated regulation of the genes involved in ureagenesis. 
Materials and Methods 
Bioinformatic Analysis of the Upstream Regulatory Regions 
Multiple and Pair-wise Alignment Analysis 
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Identification of highly conserved regions was conducted by gathering 15 
kilobases of genomic sequence 5’ of the NAGS translational start site and sequence of 
intron one in 7 mammalian species including: human (NM_153006.2), chimpanzee 
(XM_001152480.1), dog (XM_548066.2), cow (XM_618194.4), horse 
(XM_001917302.1), mouse (NM_145829.1) and rat (NM_001107053.1). The highly 
conserved regulatory regions of CPS1 were identified by gathering 15 kilobases of 
genomic sequences 5’ of the translational start site from human (NM_001875), 
chimpanzee (XM_001146604), dog (XM_856862), mouse (NM_001080809), and rat 
(NM_017072). Genomic sequences were subject to pair-wise blast comparison using 
megaBLAST 2.2.21+ [145]. Parameters included expect threshold of 10, match and 
mismatch scores of 1 and -2, respectively, gap existence and extension scores of 5 and 2 
respectively, and maximum expected value E=0.001. Regions of high conservation were 
identified as sequences with more than 80% identity that were at least 100bp and are 
present in four or more species. 
Cis-eLement OVERrepresentation Analysis 
The Cis-element OVERrepresentation (CLOVER) [146] program was used to 
predict the over-represented motifs within the highly conserved regulatory regions of 
NAGS and CPS1. CLOVER analysis of these conserved regions identified known protein 
binding DNA motifs in the TRANSFAC Pro database by calculating over-representation 
of these sequences compared to a background of ppr_build_33.fa generated from NCBI 
build 33 [147]. Matrices recognized by multiple transcription factors in the same family 
are represented by one family member unless otherwise noted. Genomic sequences of the 




The promoter and enhancer of NAGS were amplified from human genomic DNA 
with primer pairs hPromXH and hEnhXH or hPromHXrev and hEnhHXrev (Table 2), 
respectively, to introduce XhoI and HindIII restriction enzyme sites and allow subcloning 
in forward and reverse orientation. Platinum Taq PCRx DNA Polymerase (Invitrogen) 
was used for amplification with the following conditions: initial denaturation at 95˚C for 
2 min, followed by 35 cycles of denaturation at 95˚C for 30 sec, annealing at 57˚C for 30 
sec and extension at 68˚C for 1 min, and final extension at 68˚C for 6 min. Promoter and 
enhancer PCR products were ligated with TOPO-TA sequencing vector (Invitrogen) 
according to manufacturer’s instructions and referred to as TOPOProm, TOPOEnh, 
TOPOPromRev, and TOPOEnhRev respectively. Mouse Nags (mNags) promoter and 
enhancer were inserted into TOPO-TA vector following the same methods. Correct DNA 
sequences were confirmed using sequencing primers specified by Invitrogen. 
TOPOProm, TOPOEnh, TOPOPromRev, TOPOEnhRev, pGL4.10 (Promega) 
basic vector containing firefly (Photinus pyralis) luciferase luc2, and pGL4.23 (Promega) 
vector containing a minimal TATA promoter with luc2 were cut with XhoI (New 
England Biolabs) and HindIII (New England Biolabs). The vectors were treated with 
Antarctic Alkaline Phosphatase (AAP) (New England Biolabs) according to 
manufacturer’s instructions, and the NAGS regions were ligated with the vectors to form 
the plasmids in Table 3. TOPOEnh was also amplified with primer pair hEnhBS (Table 
2), to introduce BamHI and SalI restriction enzyme sites at the 5’ and 3’ ends of the 
enhancer, respectively. The amplified enhancer product and 4.10Prom were cut with 
BamHI (New England Biolabs) and SalI (New England Biolabs), the vector was treated 
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with AAP, and the enhancer was ligated with the vector (Table 3). Plasmids containing 
mouse NAGS promoter and enhancer were generated using the same methods with the 
primer pairs listed in Table 2 and plasmids in Table 3. Correct sequences were confirmed 
using primers specified by Promega. 
Point mutations in the binding sites for transcription factors Sp1, HNF-1 and NF-
Y were selected based on functional analysis of Sp1 [149,150,151], HNF-1 [152,153], 
and NF-Y [154,155] binding in other genes. Mutations were engineered by Integrated 
DNA Technologies and provided in pIDTSMART-KAN vectors (Integrated DNA 
Technology) (Table 4). Plasmids with mutant Sp1, HNF-1, and NFY were cut with XhoI 
and HindIII. Reporter plasmids pGL4.10, and pGL4.23 were cut with XhoI and HindIII 
and treated with AAP. Mutated inserts were ligated with vectors to form the plasmids 
4.10Sp1m, 4.23HNF-1m, and 4.23NFYm (Table 3). Correct sequences were confirmed 
using primers specified by Promega. 
Point mutations in the CREB binding site, c.-7T>C and c.-5T>A (Table 4), were 
selected based on functional analysis of CREB binding [156,157] in other genes and were 
engineered into the NAGS gene using QuickChange Lightning Site-Directed Mutagenesis 
Kit (Agilent) according to manufacturer’s instructions. Primers hCREBm Fw and Rv 
(Table 2) amplified 50ng of template plasmid 4.10Prom to create 4.10CREBm. The 
correct sequence was confirmed using primers specified by Promega.  
The expression vectors encoding Sp1 or HNF-1 cDNA were under control of the 





Table 2. Primer sequences used for cloning of promoter and enhancer regions of 
NAGS for reporter assays. 
Primers were used to amplify human or mouse DNA by PCR for insertion of the 
promoter and enhancer regions into sequencing and reporter assay vectors. 
Promoter Name  Promoter Sequence 
hPromXH Fw 5’-CTCGAGTGGAGGCTGCAGTGAGCTATGATT-3’ 
hPromXH Rv 5’-AAGCTTTCGCCATGACGACAACCAACTCTT-3’ 
hEnhXH Fw 5’-CTCGAGAGGACCCTTCTGGGTGGAAGTTAT-3’ 
hEnhXH Rv 5’-AAGCTTTTCCTAGGGATCCACCCAATTCAGTC-3’ 
hPromHXrev Fw 5’-AAGCTTTGGAGGCTGCAGTGAGCTATGATT-3’ 
hPromHXrev Rv 5’-CTCGAGTCGCCATGACGACAACCAACTCTT-3’ 
hEnhHXrev Fw 5’-AAGCTTAGGACCCTTCTGGGTGGAAGTTAT-3’ 
hEnhHXrev Rv 5’-CTCGAGTTCCTAGGGATCCACCCAATTCAGTC-3’ 
hEnhBS Fw 5’-GGATCCAGGACCCTTCTGGGTGGAAGTTAT-3’ 
hEnhBS Rv 5’-GTCGACTTCCTAGGGATCCACCCAATTCAGTC-3’ 
hCREBm Fw 5’-GGGGGCAAGAGTTGGTCGACGTCATGGCGAAGC-3’ 
hCREBm Rv 5’-GCTTCGCCATGACGTCGACCAACTCTTGCCCCC-3’ 
mPromXH Fw 5’-CTCGAGGCTTAGGCTGGCCTTGAATTGCTT-3’ 
mPromXH Rv 5’-AAGCTTCCATGACGACAACCAAACCCACT-3’ 
mEnhXH Fw 5’-CTCGAGGGGAATGGCACTGAGACTGTGT-3’ 
mEnhXH Rv 5’-AAGCTTGCTCTCCCTTCCAAACATCTCTTCCT-3’ 
mEnhBS Fw 5’-GGATCCGGGAATGGCACTGAGACTGTGT-3’ 
mEnhBS Rv 5’-GTCGACGCTCTCCCTTCCAAACATCTCTTCCT-3’ 
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Table 3. Plasmids generated for luciferase reporter assays. 
Name Vector Insert 
4.10Prom pGL4.10 hNAGS promoter 
4.10Enh pGL4.10 hNAGS enhancer 
4.23Enh pGL4.23 hNAGS enhancer 
4.10PromEnh 4.10Prom hNAGS enhancer 
4.10PromRev pGL4.10 hNAGS promoter reverse 
4.23EnhRev pGL4.23 hNAGS enhancer reverse 
m4.10Prom pGL4.10 mNAGS promoter 
m4.10Enh pGL4.10 mNAGS enhancer 
m4.23Enh pGL4.23 mNAGS enhancer 
m4.10PromEnh 4.10Prom mNAGS enhancer 
4.10Sp1m pGL4.10 hNAGS promoter with Sp1 mutations 
4.10CREBm pGL4.10 hNAGS promoter with CREB mutations 
4.23HNF-1m pGL4.23 hNAGS enhancer with HNF-1 mutations 
4.23NF-Ym pGL4.23 hNAGS enhancer with NF-Y mutations 
Plasmids generated by ligation of the human or mouse promoter or enhancer with pGL4 




Table 4. Mutations of Transcription Factor Binding Sites in the Promoter and 
Enhancer of human NAGS 
Factor  Wild-type Mutant 
Sp1 5’-CCGCCCCCGCC-3’  5’-AAGAACAAGAA-3’  
 5’-GGGGCGGGGG-3’ 5’-GGTTCTTTGG-3’ 
 5’-CCCCGCCCCC-3’ 5’-CCAAGAAACC-3’ 
 5’-CCCCGCCCCG-3’ 5’-CCAAGAAACG-3’ 
CREB 5’-GGTTGTCGTCATGG-3’ 5’-GGTCGACGTCATGG-3’ 
HNF-1 5’-TGGAGTTAATCATCTACTCTG-3’ 5’-TGGAGTAAGTCTGCAACCAGG-3’ 
NF-Y 5’-GGCCCCATTGGCTGCCT-3’ 5’-GGCCCCTCCAGCTG-3’ 
Transcription factor binding sites mutations in the human NAGS promoter, Sp1 and 





Cell Culture and Transfections 
Human hepatoma cells (HepG2) (donated by Dr. Marshall Summar, Children’s 
National Medical Center, Washington, DC) were cultured in complete media containing 
RPMI 1640 medium (Invitrogen) supplemented with 10% fetal bovine serum (FBS) 
(ATCC) and 5% Penicillin/Streptomycin (Invitrogen) under 5% CO2 at 37°C. Human 
alveolar basal epithelial cells (A549) (donated by Dr. Mary Rose, Children’s National 
Medical Center, Washington, DC) were cultured in complete media containing Ham’s F-
12 medium (Invitrogen) supplemented with 10% FBS and 5% Penicillin/Streptomycin. 
Human colorectal adenocarcinoma cells (Caco-2) (ATCC) were cultured in Eagle’s 
Minimum Essential Medium (Invitrogen) supplemented with 20% FBS. Cells were plated 
at a density of 5 x 105 cells/well on 24-well culture plates 24 hours prior to transfection. 
The cells (90-95% confluent for HepG2 and A549, 80-85% confluent for Caco-2) were 
then transfected using Lipofectamine 2000 reagent (Invitrogen) and cultured in 
transfection media containing medium and serum only. A total of 0.25ug of DNA was 
transfected with 0.225ug of vector expressing luc2 and 0.025ug of pGL4.74 vector 
containing Renilla reniformis luciferase (hRluc) as an internal control (Promega).  For co-
transfections 0.225ug of luc2 vector was combined with either 0.25ug of expression 
vector or empty vector pUC19 (Invitrogen), and 0.025ug of hRluc control vector.  
Reporter Assays 
24 hours following transfection, cells were assayed for both firefly and Renilla 
luciferase activity using Dual-Luciferase Reporter Assay System (Promega) and Berthold 
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Centro 960 luminometer (Berthold) according to the manufacturer’s protocol. All 
reporter assay measurements were corrected for transfection efficiency by normalizing 
the firefly luciferase signal to the Renilla luciferase values. Expression level of each 
construct was determined relative to luciferase expression under control of the NAGS 
promoter in each cell line. All results are an average of three independent experiments 
that were each carried out in triplicate. Values were expressed as mean ± SEM and 
analyzed using Student’s t-test.  
5’Rapid Amplification of cDNA Ends (RACE) 
5’ RACE (Version 2.0; Invitrogen) was performed using RNA isolated from 
donated mouse livers by Trizol reagent (Invitrogen).  RNA from mouse small intestine 
(Origene), human duodenum (Ambion), or human liver (Ambion) was commercially 
available. Products were synthesized with human or mouse NAGS specific primers 
complementary to sequence within Exon 1 (Table 5). All reactions began with 5ug of 
total RNA and the RACE procedure was conducted according to manufacturer’s 
instructions. Second strand synthesis was conducted using Ex Taq Polymerase (TaKaRa 
Bio Inc.) PCR products were subcloned into pCR 2.1-TOPO vector (Invitrogen) and 
RACE products were sequenced with primers specified by the manufacturer. 
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Table 5. Primer sequences used to determine transcription start sites of NAGS with 
5’ RACE. 
Primer Name Primer Sequence 
hNAGS-GSP1 5’- GACGGCGAAGGGCTTGT-3’ 
hNAGS-GSP2 5’- GTCTGGAACTGCGTGAGCC-3’ 
hNAGS-GSP2B 5’- CGACGCACTGGTTCAGGA-3’ 
mNAGS-GSP1 5’- CATGACGGCGAAGGGCTTGT-3’ 
mNAGS-GSP2 5’- GGTAGCAGGTCTGGAATTGCGTG-3’ 
mNAGS-GSP2B 5’- CGATGAGCCAGTGGCGTGCTTC-3’ 
Primers were designed according to manufacturer’s instructions and used to determine 
transcription start sites of human and mouse NAGS in liver and small intestine RNA 




Avidin-Agarose DNA Protein Pull-Down Assay 
Biotinylated DNA Probes 
Probes for Avidin-Agarose DNA-Protein Pull-Down Assays were generated by 
PCR amplification of genomic DNA isolated from donated mouse tails using Pure Gene 
DNA Purification Kit (Gentra). Probes were generated using biotinylated or non-
biotinylated forward primers and non-biotinylated reverse primers with Platinum Taq 
PCRx DNA Polymerase (Invitrogen) and amplification conditions: initial denaturation at 
95˚C for 2 min, followed by 35 cycles of denaturation at 95˚C for 30 sec, annealing at 
60˚C for 30 sec and extension at 68˚C for 1 min, and final extension at 68˚C for 6 min. 
The mNags promoter regions A and B (Figure 3) were amplified with primer pair 
mNAGS-Prom Region A, from +97 to -259, relative to the translation initiation codon 
and with mNAGS-Prom Region B, from -302 to -776, respectively (Table 6). A region of 
mNags, that is not highly conserved in mammals, -1056 to -1320, was amplified using 
primer pair mNAGS-Prom-NC to serve as a negative control for the promoter regulatory 
region. The enhancer region of mNAGS, spanning from -2834 to -3167, was amplified 
using forward primer pair mNAGS-enh. The non-conserved probe, for use as a negative 
control for the enhancer region, was the amplification product of primer pair mNAGS-
Enh-NC spanning -5569 to -5997 upstream of mNags. For additional negative controls, 
non-biotinylated probes were generated using each primer pair.  
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Table 6. Primer sequences used to generate DNA probes of the specified regions of 
mNags. 
Primer Name Primer Sequence 
mNAGS-Prom Region A Fw 5’-AATCTGACCTTCGTGACCCTCACT-3’ 
mNAGS-Prom Region A Rv 5’- CACTCAGTCTCCGTGAGCCC-3’ 
mNAGS-Prom Region B Fw 5’-ACATTCCCAAATGTGGCCATCACC-3’ 
mNAGS-Prom Region B Rv 5’-AAAGCGCTCAGATGTCCTAGGTGT-3’ 
mNAGS-Prom-NC Fw 5’-AGCTGTACAGATGGTTGTGAGCCT-3’ 
mNAGS-Prom-NC Rv 5’-TCAGCGGGTAAGAGTACTGACTGCT-3’ 
mNAGS-Enh Fw 5’-GCTTTGTTGGAAGGTCAAGTCG-3’ 
mNAGS-Enh Rv 5’-GTGCCCTTCATCTTTGTCCCA-3’ 
mNAGS-Enh-NC Fw 5’-TAGGGCGTGTTCAAGACAGGGTTT-3’ 
mNAGS-Enh-NC Rv 5’- AGCTTGGTGGTGAGTGCCTTTAGT-3’ 
Primers were used to generate DNA probes, by PCR, of the promoter, enhancer, or non-
specific specified regions of mNags.  
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Preparation of Nuclear Extracts 
Nuclear extract was isolated from donated adult mouse livers of C57BL/6 mice 
using Nuclear Extraction Kit (Origene) according to manufacturer’s instructions. The 
protein concentration of the nuclear extract was determined using bovine serum albumin 
as the protein standard with Bradford Assay dye concentrate reagents (Bio-Rad). On 
average, 10mg of nuclear protein was obtained from mouse liver.  
Binding Protocol and Immunoblot 
For the avidin-agarose protein-DNA pull-down assay [158] 1 mg of nuclear 
extract in PBS buffer containing inhibitors (PBSI; 1x PBS with 0.5mM PMSF, 25mM β-
glycerophosphate, mM NaF), 15 ug of DNA probe, and avidin-agarose beads (Sigma) 
were combined and incubated for 16 hrs on a rotating shaker at 4°. The probe and bead 
concentrations were in excess to ensure complete pull-down of DNA–protein complexes. 
Following incubation, the supernatant was reserved while the beads were washed 3 times 
with cold PBSI and then resuspended and boiled in Laemmli protein denaturing buffer 
(Bio-Rad) with 0.2 M DTT. The supernatant was also mixed with protein denaturing 
buffer and DTT and then boiled prior to application on a 10% SDS–polyacrylamine gel. 
The proteins were separated by electrophoresis, transferred to a nitrocellulose membrane, 
and then identified by immunoblotting using primary antibodies at 1:2000 dilution of 
antibody to Sp1 (Santa Cruz Biotech; Millipore), 1:1000 dilution of CREB-1α/β (Santa 
Cruz Biotech), and 1:3000 dilution of C/EBPα/β (Santa Cruz Biotech) for the promoter 
region and 1:500 dilution of HNF-1α/β (Santa Cruz Biotech), 1:1000 dilution of NF-Yα 
(Santa Cruz Biotech), 1:1000 dilution of AP-2 (Santa Cruz Biotech), and 1:2000 dilution 
of SMAD2/3 (Santa Cruz Biotech) for the -3kb conserved region. The membrane was 
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than incubated with 1:20,000 dilution of donkey anti-rabbit secondary antibody 
conjugated to horseradish peroxidase (Pierce) and bands were visualized using 
SuperSignal West Pico Kit (Pierce) according to manufacturer’s instructions.  
Chromatin Immunoprecipitation 
Tissue Preparation and DNA Immuniprecipitation 
Donated livers from adult C57BL/6 mice were minced and chromatin was 
precipitated using SimpleChIP Enzyme Chromatin Kit (Origene) with the variation for 
whole tissue.  Briefly, fresh tissue was minced and washed with PBS including Protease 
Inhibitor Complete tablets (Roche). Proteins and DNA were cross-linked with 1.5% 
formaldehyde, and tissue was disaggregated with dounce homogenizer. Chromatin was 
sheared to an approximate size of 100-1000bp by micrococcal nuclease digestion 
followed by sonication. Immunoprecipitation was conducted using antibodies to 
transcription factors Sp1 (Millipore), CREB (Santa Cruz Biotech), C/EBP (Santa Cruz 
Biotech), HNF-1 (Santa Cruz Biotech), NF-Y (Santa Cruz Biotech), SMAD2 (Santa Cruz 
Biotech) and AP-2 (Santa Cruz Biotech) and control antibodies to histone H3 and non-
specific rabbit IgG (Cell Signaling Technologies). Chromatin was eluted from protein G 
agarose beads, cross-linking was reversed, and DNA was purified according to 
manufacturer’s instructions.   
Real-Time PCR Quantification 
ChIP enriched DNA samples included 2% input control and dilutions for a 
standard curve, positive control immunoprecipitate from anti-histone H3 antibody 
sample, negative control immunoprecipitation from anti-rabbit IgG antibody, no antibody 
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control, water control, and test antibodies. Enriched DNA was subject to quantitative 
real-time PCR using iTaq SYBR Green Supermix with ROX (Bio-Rad) and gene specific 
primers (Table 7) including negative locus primers to Chemokine ligand 2 (MIP-2) on a 
7900HT Fast Real-Time PCR System (Applied Biosystems). Amplification conditions 
included initial denaturation at 95˚C for 2 min, followed by 50 cycles of denaturation at 
95˚C for 30 sec, annealing at 60˚C for 30 sec and extension at 72˚C for 30 sec, with 
dissociation steps of 95° for 15 sec followed by 50° for 15 sec and finally 95° for 15 sec. 
Samples were amplified and analyzed using 7900HT Sequence Detection System 
Software (Applied Biosystems). Values were expressed as mean ± SEM and analyzed 
using Student’s t-test.  
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Table 7. Primer sequences for quantitative real-time PCR analysis of chromatin 
immunoprecipitation samples. 
Primer Name Sequence 
mNAGS promoter FW  CATACACAAGGGGCGGAGA 
mNAGS promoter RV GGGTTCTTAACTTGCCGCTGA 
mNAGS enhancer FW GGCCTTCCGTAAGTAGGAAGCA 
mNAGS enhancer RV CCCACCTAGAGGGCTGTGT 
MIP-2 FW GAAGGGCAGGGCAGTAGAAT 
MIP-2 RV ATGCACGATGTCTGGAAAAG 
mCPS1-CEBP Fw GGAACATCTCTGGACATCA 
mCPS1-CEBP Rv2 CCAATTTGTTTGTAACCAGTGTGAA 






Selected regions of non-coding DNA upstream of NAGS are highly conserved  
A 15 kilobase region of genomic DNA 5’ of the translational start site of NAGS 
and sequence of the first intron from human, chimpanzee, dog, horse, cow, mouse and rat 
were aligned and compared using pair-wise BLASTn. Comparisons showed three highly 
conserved regions upstream of human NAGS at -57 to -284, -498 to -576, and -2978 to -
3344 relative to the start ATG, and no significant conservation within the intron or 
between -5 and -15kb upstream (Figure 3). The region within -1kb of the translational 
start site was designated as the putative promoter while the region 3kb upstream was 
designated a putative regulatory element. Figure 3 also shows an alignment of 
mammalian NAGS genes using UCSC Genome Browser software phastCons (green) and 
phyloP (blue), which identified three non-coding regions of conservation located 3kb 
upstream, immediately upstream, and within the first intron of NAGS, respectively 
(Figure 3). The phastCons, phyloP and our analyses of conservation within the NAGS 
gene differed due to different algorithms that were used to identify regions of 
conservation [145,159,160].  
To validate our strategy for identification of conserved regions, the same analyses 
were conducted for CPS1, a gene in which a proximal promoter and an enhancer element 
located 6.3kb upstream of rat Cps1, have been characterized [70,161,162]. 15 kb of CPS1 
genomic DNA sequence 5’ of the translational start site was collected from human, 
chimpanzee, dog, mouse and rat and compared using pair-wise BLASTn.  Five regions of 
high conservation were identified including the previously reported proximal promoter 
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located immediately upstream of the translation initiation codon and the enhancer at -
7392 to -7966 relative to ATG of the human CPS1 gene (Figure 4). In addition, three 
previously unknown regions, termed A, B and C, were also identified at -5, -10.5 and -12 
kb relative to CPS1 translation initiation codon (Figure 4). PhastCons and phyloP 
alignment of mammalian genomic DNA identified the same 5 conserved regions (Figure 
4).  
Highly conserved, non-coding regions of NAGS function as promoter and 
enhancer elements for gene transcription 
Reporter assays were used to examine the functionality of each of the following: 
wild type NAGS promoter (4.10Prom), control reversed promoter (4.10PromRev), 
enhancer alone (4.10Enh), promoter and enhancer (4.10PromEnh), and enhancer in both 
orientations with the heterologous TATA-box promoter (4.23Enh and 4.23EnhRev) by 
measuring the expression of a luciferase reporter gene in cultured HepG2 cells (Figure 
5A). Vectors pGL4.13, pGL4.23, and pGL4.10 containing firefly luciferase luc2, with an 
SV40 promoter, a minimal TATA-promoter, or without a promoter respectively, were 
used as positive, baseline reference, and negative assay controls. Vector pGL4.74, 
containing Renilla luciferase hRluc, was co-transfected with each plasmid to control for 





Figure 3. Upstream regions of the mammalian NAGS genes are highly conserved.  
Conservation of mammalian NAGS DNA by phastCons (green) and phyloP (blue) 
algorithms is shown with the highly-conserved regions indicated in red boxes. Pair-wise 
BLASTn analysis of mammalian non-coding regions of NAGS identified highly 
conserved sequences upstream of the translational start site termed the promoter (purple) 





Figure 4. Regions Upstream of mammalian CPS1 genes are highly conserved.  
Three new highly conserved regions were identified within 15kb 5’ of the CPS1 
translational start site. Conservation algorithms phastCons (green) and phyloP (blue) 
from the UCSC genome browser indicate regions that are highly conserved across all 
mammals (A). Pair-wise blast analysis of human, chimpanzee, dog, mouse, and rat 5’ 
non-coding region of CPS1 were used to identify two known and three previously 
unknown regions of high conservation, referred to enhancer/repressor regions A, B, and 
C. Highly conserved regions within the CPS1 5’ non-coding sequence include the 
proximal promoter, region A, the enhancer, region B, and region C. 
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The human NAGS promoter alone (plasmid 4.10Prom), stimulated transcription of 
the luciferase gene while the upstream regulatory region (plasmid 4.10Enh) alone, did not 
(Figure 5A). When the NAGS promoter and upstream regulatory region were both present 
(4.10PromEnh plasmid), transcription increased by 50% compared to the promoter alone 
confirming that the upstream conserved region can function as an enhancer of 
transcription. When the NAGS enhancer was paired with a heterologous promoter 
containing a TATA-box, in the 4.23Enh construct, it activated transcription of luciferase 
but the activity was only one third of that observed for 4.10PromEnh plasmid. Neither 
backbone vector 4.10 nor 4.23 containing the minimal TATA-box stimulated expression 
of the luciferase gene. As expected, positive control vector 4.13, containing a strong 
promoter, activated transcription in this cell culture system (Figure 5A). The promoter in 
the reverse orientation (4.10PromRev) did not activate luciferase expression indicating 
that the NAGS promoter acts in a direction dependent manner (Figure 5B). The ability of 
the NAGS enhancer (4.23EnhRev) to stimulate transcription with the heterologous 
promoter was orientation independent (Figure 5C). Similar results were obtained for 
reporter assays using mouse promoter and enhancer (Figure 6). 
Transcription of NAGS initiates at multiple sites  
Following discovery of the NAGS promoter, the transcriptional start sites (TSS) in 
human and mouse liver and small intestine were identified using 5’ RACE (Figure 7A 
and B). Cloned and sequenced amplification products from 5’RACE were aligned along 
the 5’ non-coding region of NAGS with TSS identified in the Database of Transcriptional 
Start Sites (DBTSS) and expressed sequence tags (ESTs) from Genbank. Results suggest 
that NAGS has multiple TSS and that some may be species and tissue-specific. Combined 
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5’RACE, DBTSS, and Genbank results indicate that within human liver, the most 
frequently occurring TSS was at -42bp upstream of the ATG codon, while in human 
small intestine it was at -146bp (Figure 7A). Within mouse tissues, no dominant TSS was 
evident, but transcription of the NAGS gene initiated most often from -20bp and -108bp 
in liver and -20bp and -95bp in small intestine (Figure 7B). Figure 7 also shows several 
other rare TSS that were identified. 
Transcription factors bind conserved motifs within the promoter and enhancer of 
NAGS 
When promoters and enhancers from six mammalian NAGS genes were aligned, 
there were multiple regions of base pair conservation (Figure 8). Cis-eLement OVER-
representation (CLOVER) software analysis was employed to identify transcription 
factor binding motifs in regulatory regions of human, chimpanzee, horse, cow, dog, 
mouse, and rat NAGS. Analyses of the region +9 to -996 bp (relative to the translational 
start codon, promoter, Table 8) and –2866 to -3620 bp (enhancer, Table 9) predicted 
several transcription factor binding motifs that are expressed in the liver, but no TATA-
box for transcription initiation. Sp1 binding sites, within the promoter, and the HNF-1 
binding motif, within the enhancer, received the highest over-representation scores, but 





Figure 5. Highly conserved regulatory regions, upstream of the NAGS gene, function 
as promoter and enhancer elements.  
In liver derived cells the NAGS promoter (4.10Prom), promoter + enhancer 
(4.10PromEnh), enhancer with TATA promoter (4.23Enh), and positive control promoter 
vector (pGL4.13) significantly simulate transcription while the enhancer (4.10Enh), basic 
TATA protein alone (pGL4.23), and vector (pGL4.10) do not stimulate transcription 
above baseline (A). Reverse insertion of the promoter (4.10PromRev) did not stimulate 
transcription compared to 4.10Prom and pGL4.10 vector (B), but reverse enhancer 
(4.23EnhRev) significantly stimulated transcription compared to 4.23Enh and pGL4.23 
vector (C). Calculated results are an average of three independent experiments that were 
each carried out in triplicate, normalized to Rluc expression, and expressed relative to the 
promoter for each experiment with error reported as ±SEM. Different lowercase letters 




Figure 6. Highly conserved regulatory regions, upstream of the mouse Nags gene, 
function as promoter and enhancer elements.  
Mouse promoter (m4.10Prom), promoter + enhancer (m4.10PromEnh), and enhancer 
with TATA promoter (m4.23Enh) stimulated transcription in HepG2 cells while enhancer 
lacking a promoter (m4.10Enh) did not. Calculated results are an average of three 
independent experiments that were carried out in triplicate, normalized to Rluc 
expression, and expressed relative to the promoter for each experiment with error 





Figure 7. Transcription start sites (TSS) are species and tissue specific.  
TSS identified in the promoter of NAGS by 5’RACE analysis (blue circles), the Database 
of Transcriptional Start Sites (DBTSS) (green circles) and 5’ termination sites of 
Expressed Sequence Tags (ESTs) from Genbank (orange circles) were aligned on the 
DNA sequence 5’ of the human (A) and mouse (B) NAGS coding sequence. The arrow 




Figure 8. Sequence alignment of NAGS promoters and enhancers from seven 
mammalian species indicate conserved motifs.  
DNA sequence of the promoter (A) and enhancer (B) regions were aligned using 
CLUSTALW alignment software. CLOVER analysis was used to identify transcription 
factor binding motifs. Binding sites for C/EBP (green), Sp1 (red), CREB/ATF (pink), 
AP-2 (purple), HNF-1 (blue), NF-Y (olive), and SMAD 3 (cyan) were highly conserved. 
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Table 8. CLOVER analysis of the promoter region with sequence information for 
human and mouse NAGS. 
Sequence file: NAGS_promoter.txt (7 sequences, 7031 bp, 52.8% C+G) 
Motif file: transfac_pro_n (588 motifs)   
    
Motif                       Raw score P-value from randomizing 
M00933|Sp1                        20.3 0  
M00196|Sp1                     19.8 0  
M00932|Sp1                   19.7 0  
M00931|Sp1                  19.6 0  
M00255|GC box                 14.7 0.0001  
M00257|RREB-1           11.3 0.006  
M00008|Sp1              8.38 0  
M00721|CACCC-binding factor  8.05 0.001  
M00691|ATF1         5.05 0  
M00916|CREB        1.42 0.006  
M00017|ATF     1.03 0.003  
    
Motif                         Location      Strand   Sequence                        
>humanNAGS_promoter    
M00932|Sp1                      22 -   34     +                      atagggtgggact   
M00932|Sp1    138 -  150     +                      agtgggaggactg   
M00008|Sp1    233 -  242     +                         tgggcatggt   
M00257|RREB-1    244 -  257     -                     gtgtgcatttgtgg   
M00255|GC box    302 -  315     +                     gggaggtggaggct   
M00932|Sp1    302 -  314     +                      gggaggtggaggc   
M00257|RREB-1    474 -  487    -                     aggggtgttttgag   
M00916|CREB    542 -  555     +                     ggtaacctcatggt   
M00255|GC box    607 -  620     -                     accacccgcccccg   
M00932|Sp1    608 -  620    -                     ccacccgcccccg   
M00255|GC box    613 -  626     -                     cgcccccgccctcc   
M00932|Sp1    614 -  626     -                      gcccccgccctcc   
M00932|Sp1    618 -  630     -                      ccgccctcccact   
M00935|NF-AT    646 -  655     -                         ctctttccag   
M00932|Sp1    850 -  862     +                      caggggcggggga   
M00255|GC box    850 -  863     +                     caggggcgggggag   
M00255|GC box    869 -  882     -                     tggccccgccccct   
M00932|Sp1    870 -  882     -                      ggccccgccccct   
M00255|GC box    940 -  953    -                     ggaccccgccccga   
M00932|Sp1    941 -  953     -                      gaccccgccccga   
M00255|GC box    961 -  974     -                     cagccccgcccaac   
M00196|Sp1    962 -  974     -                      agccccgcccaac   
M00017|ATF   1041 - 1054     -                     ggttgtcgtcatgg   
M00916|CREB   1042 - 1055     +                     gttgtcgtcatggc   
    




M00691|ATF1     53 -   63     -                        tgagttcaagg   
M00932|Sp1    247 -  259     -                      atcaccgcccccc   
M00932|Sp1    252 -  264     -                      cgccccccccccc   
M00257|RREB-1    274 -  287     -                     gttttgttttgtgt   
M01082|BRCA1:USF2    566 -  573     -                           caacagga   
M00255|GC box    598 -  611    -                     ggaccacaccccct   
M00932|Sp1    599 -  611     -                      gaccacaccccct   
M00721|CACCC-binding factor    785 -  800     -                   ccatacacaaggggcg   
M00932|Sp1    793 -  805     +                      aaggggcggagaa   
M00932|Sp1    813 -  825     -                      ggcgccaccctct   
M00257|RREB-1    844 -  857     +                     cctcaaacgcaccc   
M00255|GC box    882 -  895     -                     ccatcccgccccga   
M00932|Sp1    883 -  895    -                     catcccgccccga   
M00721|CACCC-binding factor    959 -  974     +                   cgtcacctgtgggtgg   
M00257|RREB-1    965 -  978     -                     ctgtgggtgggggg   
M00255|GC box    966 -  979     +                     tgtgggtggggggg   
M00196|Sp1    966 -  978     +                      tgtgggtgggggg   
M00932|Sp1    970 -  982     +                      ggtgggggggacg   
M00932|Sp1    974 -  986     +                      ggggggacgagtg   
M00257|RREB-1    982 -  995     -                     gagtgggtttggtt   
M00257|RREB-1    986 -  999     -                     gggtttggttgtcg   
M00017|ATF    992 - 1005     -                     ggttgtcgtcatgg   




Table 9. CLOVER analysis of the enhancer region with sequence information for 
human and mouse NAGS. 
Sequence file: NAGS_enhancer.txt (7 sequences, 5280 bp, 55.2% C+G) 
Motif file: transfac_pro_n (588 motifs)  
    
Motif                     Raw score   P-value from randomizing 
M00206|HNF1              22.4 0  
M01011|HNF1               18.9 0  
M00687|alpha-CP1 17.9 0  
M00287|NF-Y                    10.5 0  
M00444|VDR                10.1 0.007  
M00056|myogenin / NF-1 8.02 0  
M00701|SMAD3 6.29 0.001  
M00185|NF-Y                 5.21 0.0001  
M00800|AP-2                4.91 0.01  
M00188|AP-1                 2.38 0.004  
M00514|ATF4                2.36 0.006  
    
Motif                     Location    Strand   Sequence                       
>humanNAGS_enhancer    
M01011|HNF1                19 -  39     +              tactgtcaaatgtcaacccca   
M00444|VDR   378 - 392    -                   tgaccccagacactc   
M01011|HNF1   477 - 497    -              tggagttaatcatctactctg   
M00188|AP-1   480 - 490     -                        agttaatcatc   
M00287|NF-Y   507 - 522     -                   ggccccattggctgcc   
M00687|alpha-CP1   510 - 520     -                        cccattggctg  
M00185|NF-Y   510 - 520     -                        cccattggctg   
M00800|AP-2   514 - 529     -                  ttggctgcctggggac   
M00701|SMAD3   515 - 523     +                          tggctgcct   
    
>mouseNAGS_enhancer    
M00188|AP-1    10 -  20     +                        gatggctcagt   
M00444|VDR   350 - 364     -                    ggacccagtggcccc   
M00185|NF-Y   353 - 363     -                        cccagtggccc   
M01011|HNF1   378 - 398     -              tggtgttaatcattcactcgg   
M00188|AP-1   381 - 391    -                        tgttaatcatt   
M00206|HNF1   381 - 397     +                  tgttaatcattcactcg   
M00287|NF-Y   408 - 423     -                   ggtcccattggctgcc   
M00185|NF-Y   411 - 421     -                        cccattggctg   
M00687|alpha-CP1   411 - 421     -                        cccattggctg   
M00800|AP-2   415 - 430    -                  ttggctgcctggggac   
M00701|SMAD3   416 - 424     +                          tggctgcct   
M00056|myogenin / NF-1   432 - 460     +      cagccctctaggtgggagcccagccagta   




Next, over-represented motifs were mapped on the CLUSTALW alignments 
(Figure 8A and B) and motifs with high conservation, having been identified in at least 
four out of the seven mammalian species, were examined further. Throughout the 
promoter, five binding sites for Sp1 were highly conserved, two of which were conserved 
in all examined species. A binding site recognized by CREB and Activating 
Transcription Factor-1 (ATF-1) was conserved in four species and overlapped with the 
translation start codon; a C/EBP binding site was identified farther upstream in region B 
of the promoter (Figures 8A & 9A). Within the enhancer, a binding site for HNF-1 was 
conserved in all species. Overlapping binding sites for NF-Y, AP-2 and Mothers Against 
Decapentaplegic Homolog 3 (SMAD3) were also conserved in all species, while an 
additional AP-2 binding site, located 5’ of the HNF-1 site, was conserved in four out of 
seven species (Figure 8B & 9B).  
To validate computational strategy for identification of transcription factor 
binding sites, the enhancers of human, chimpanzee, dog, mouse, and rat CPS1 were 
analyzed using CLOVER, and the experimentally identified binding motifs for C/EBP, 
CREB, GR, AP-1 and HNF-3 [70,161,162] were detected along with additional 
unreported motifs for HNF-4, AR, C/EBP and HNF-3 (Table 10). The detection of 
experimentally confirmed binding motifs in CPS1 has made the use of CLOVER for 




Figure 9. DNA-protein avidin-agarose pull-down assay results confirm transcription 
factor binding.  
Two probes for the promoter (A) and one probe for the enhancer (B) encompass the 
highly conserved transcription factor binding motifs of NAGS. The motif colors reflect 
the colors used in figures 8A and B. Assays followed by immunoblot confirmed binding 
of Sp1 and CREB, but not C/EBP within the promoter (C) and HNF-1 and NF-Y, but not 
SMAD3 or AP-2 within the enhancer regions (D). Lanes 1-4 represent precipitated 
proteins from mouse liver nuclear extract bound to biotinylated probes of the regions of 
interest (Lane 1), non-biotinylated probes of the regions of interest (Lane 2), biotinylated 
probes of non-specific regions (Lane 3), and no probe (Lane 4). Lanes 5-8 represent 
supernatant fluid from overnight incubation of biotinylated probes of the region of 
interest (Lane 5), non-biotinylated probes of the region of interest (Lane 6), biotinylated 
probes of the non-specific regions (Lane 7), or no probe (Lane 8). Immunoblots are 




Table 10. CLOVER analysis of the enhancer region with sequence information for 
human and mouse CPS1. 
Sequence file: CPS1_enhancer_element.txt (5 sequences, 2875 bp, 40.4% C+G) 
Motif file: transfac_pro_n (588 motifs)    
     
Motif                       Raw score   P-value from randomizing  
M00447|AR                   10.8 0   
M00724|HNF3alpha            10.1 0   
M00912|C/EBP                        6.34 0   
M00117|C/EBPbeta            6.07 0.001   
M00109|C/EBPbeta            5.83 0.002   
M00123|c-Myc:Max    4.52 0   
M00921|GR              4.09 0.002   
M00967|HNF4, COUP        3.64 0.004   
M00116|C/EBPalpha  3.44 0.006   
M00707|TFIIA     3.26 0.003   
M00981|CREB, ATF   2.52 0   
M00801|CREB         1.01 0   
     
Motif                       Location   Strand   Sequence                       Score 
>humanCPS1_enhancer     
M00921|GR   256 - 263     +                          cctgttct   6.99 
M00981|CREB, ATF   264 - 272     -                         ctacgtcat   8.05 
M00109|C/EBPbeta   325 - 338    -                    atgttgcaccacat   7.08 
M00123|c-Myc:Max   331 - 342     +                      caccacatgctt   7.87 
M00707|TFIIA   349 - 360     -                      gatcctcaaata   6.31 
M00967|HNF4, COUP   375 - 383     +                        agggtccag   7.47 
M00921|GR   385 - 392     +                          agtgtcct   6.49 
M00109|C/EBPbeta   454 - 467     -                    atcttgcaaaatca   7.41 
M00724|HNF3alpha   470 - 480     +                       tgtttactctt   8.11 
M00724|HNF3alpha   489 - 499     -                       ttaagaaaaca   6.11 
M00447|AR   508 - 522     +                  agagttgtttgttct   6.57 
M00724|HNF3alpha   513 - 523     +                       tgtttgttctg   9.29 
M00921|GR   515 - 522     +                          tttgttct   6.65 
M00117|C/EBPbeta   560 - 573     -                    tcgttgtgcaaaga   6.17 
     
>mouseCPS1_enhancer     
M00109|C/EBPbeta   117 - 130     +                    agtttgtgaaagca   6.03 
M00981|CREB, ATF   284 - 292    -                         caacgtcat   6.98 
M00117|C/EBPbeta   311 - 324     +                    ctcttgcttcacta   6.35 
M00967|HNF4, COUP   337 - 345     +                         caagtccat   6.3 
M00109|C/EBPbeta   342 - 355    -                    ccattacacaacat   8.34 
M00123|c-Myc:Max   372 - 383     +                      catcacacgtgt   6.82 
M00967|HNF4, COUP   394 - 402     +                         agggtccag   7.72 
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M00921|GR   404 - 411     +                          agtgtcct   6.49 
M00001|MyoD   428 - 439     -                     taccacctctct   6.18 
M00189|AP-2   440 - 451     +                      ctcctcatggcg   6.06 
M00912|C/EBP   470 - 481     +                      cttgcaaaatca   7.28 
M00724|HNF3alpha   486 - 496     +                       tgtttactctt   7.9 
M00447|AR   522 - 536     +                   agagcagtttgttct   11 
M00724|HNF3alpha   527 - 537     +                       agtttgttctg   6.71 
M00921|GR   529 - 536     +                          tttgttct   6.54 
M00921|GR   534 - 541     +                          tctgttca   6.31 
M00707|TFIIA   548 - 559     +                     tataagaggggg  8.67 
M00912|C/EBP   562 - 573     -                      ggttttggcaat   6.11 
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A DNA-protein pull-down assay was devised to test the bioinformatic prediction 
of specific binding sites. Two biotin-labeled DNA probes for the promoter (Figure 9A) 
encompassed regions A and B (Lane 1 in Figure 9C) and one probe (Figure 9B) 
encompassed the enhancer (Lane 1 in Figure 9D). A biotinylated probe to a region 
upstream of the NAGS gene, lacking any highly conserved motifs (Lane 3 in Figures 9C 
and D), and non-biotinylated probes to region A or B (Lane 2 in Figures 9C and D) were 
used as negative controls. The supernatant fluid from each pull-down was included as a 
positive control for the presence of the transcription factor protein (Lanes 5-8). Intensities 
of bands corresponding to each transcription factor in supernatant fluids were also used 
as indicators of pull-down efficiency. 
Factors Sp1 and CREB bound to the probe of promoter region A (Lane 1 in 
Figure 9C). Sp1 also bound to the probe of promoter region B (data not shown) while 
C/EBP did not bind to this probe (Lane 1 in Figure 9C). Within the enhancer region, 
transcription factors HNF-1 and NF-Y bound to the probe, however SMAD2/3 and AP2 
did not (Lane 1 in Figure 9D).  Binding of Sp1, CREB, C/EBP, HNF-1, NF-Y, 
SMAD2/3, and AP-2 was not detected in the negative controls (Lanes 2–4 in Figures 9C 
and D) while each transcription factor was detected in the positive controls of liver 
nuclear extract supernatants (Lanes 5-8 in Figures 9C and D). Each immunoblot result is 
representative of at least three replicate experiments.   
Binding of transcription factors to the predicted motifs was also confirmed using 
Chromatin Immunoprecipitation (ChIP) followed by Real-Time PCR. Measurement 
compared the enrichment of target DNA regions to the negative control locus MIP-2. 
ChIP with Sp1 and CREB antibodies significantly enriched the NAGS promoter DNA 
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compared to MIP-2 (p<0.005 and p<0.05, respectively; Figure 10A). ChIP with C/EBP 
antibody did not enrich the NAGS promoter DNA compared to the negative locus 
(p>0.05; Figure 10A). The NAGS enhancer was enriched in chromatin 
immunoprecipitated with antibodies against HNF-1 and NF-Y (p<0.005 and p<0.05, 
respectively; Figure 10B), but not with antibodies against AP-2 and SMAD2/3 (p>0.05; 
Figure 10B). Thus, pull-down and ChIP assays confirmed that Sp1 and CREB bind along 
the NAGS promoter and HNF-1 and NF-Y bind along the enhancer.  
Transcription factors and binding motifs are functionally important 
Reporter assays in liver hepatoma cells with mutated transcription factor binding 
motifs demonstrate the functional importance of each site. Following these sequence 
substitutions (Table 4), transcription factor binding motifs were no longer detected by 
CLOVER. Within the promoter, point mutation in the Sp1 binding sites decreased the 
expression of reporter gene by 75% (p<0.005) and point mutations in the CREB binding 
site resulted in a 40% decrease (p<0.005; Figure 11A). Point mutations in the HNF-1 or 
NF-Y binding sites, in the enhancer, decreased expression of luciferase reporter by 50% 




Figure 10. Chromatin Immunoprecipitation (ChIP) results confirm transcription 
factor binding.  
ChIP with transcription factor antibodies was compared to negative control IgG antibody. 
Real-Time PCR using promoter or enhancer specific primers was compared to primers 
for the negative locus MIP-2. The results confirmed that Sp1 and CREB but not C/EBP 
bind within the promoter (A) and HNF-1 and NF-Y but not AP-2 or SMAD2/3 bind 
within the enhancer region (B) of NAGS. Calculated error was from three replicate 
experiments and reported as ± SEM. One asterisk (*) indicates p<0.05 and two asterisks 





Figure 11. Transcription factors Sp1, CREB, HNF-1, and NF-Y are functionally 
important for stimulating expression of reporter gene transcription.  
Mutagenesis of the putative transcription factor binding sites significantly decreases 
transcription by the promoter (A) and the enhancer with TATA promoter (B) in liver 
derived cells when compared to non-mutated sites. Addition of Sp1 with the promoter 
(A) and HNF-1 with the enhancer (B) increases transcription driven by non-mutated 
constructs. Calculated results are an average of three independent experiments that were 
each carried out in triplicate, normalized to Rluc expression, and expressed relative to the 
promoter for each experiment with error reported as ±SEM. Different lowercase letters 
indicate statistically significant differences (p<0.05). 
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While these results confirm that each motif is important for transcription, the 
functional importance of Sp1 and HNF-1 proteins is demonstrated by co-expression of 
the proteins with reporter assay constructs. Co-transfection of Sp1 expression plasmid 
with the NAGS promoter (4.10Prom) increases expression of luciferase more than 50% 
(P<0.005; Figure 11A) while co-transfection of HNF-1 expression construct with the 
enhancer and minimal TATA promoter (4.23Enh), increases expression of the reporter 
gene by 25% (p>0.05; Figure 11B) suggesting that endogenous Sp1 and, less so, HNF-1 
do not saturate their binding motifs on the transfected reporter plasmids.  
Reporter assays to compare the effect of the enhancer in liver, intestine and lung 
cells, included data that were normalized to the reporter expression driven by the 
promoter. While the NAGS enhancer (4.10PromEnh) increased expression of the reporter 
gene by 50% in liver derived cells (Figure 5A), expression of the luciferase gene did not 
increase in the intestine or lung derived cells (Figure 12) and therefore the enhancer was 
determined to be tissue specific. When HNF-1 expression plasmid and 4.10PromEnh 
were co-transfected into intestine and lung derived cells, transcription was stimulated to 
levels that were not significantly different from 4.10PromEnh in liver cells (p>0.05) 
(Figure 12). Because intestine and lung derived cells lack HNF-1 (data not shown), this 
demonstrated the importance of HNF-1 and NAGS enhancer for the tissue specificity of 




Figure 12. The NAGS enhancer shows tissue specificity.  
The enhancer with NAGS promoter (4.10PromEnh) increases transcription relative to the 
promoter in liver derived cells but not in intestine or lung derived cells (cyan bars) 
without the addition of HNF-1 protein (teal bars). Calculated results are an average of 
three independent experiments that were carried out in triplicate, normalized to Rluc 
expression, and expressed relative to the promoter for each experiment with error 




In this study we used bioinformatic analyses to predict regulatory regions based 
on the hypothesis that non-coding DNA sequences that are highly conserved between 
species are important for gene regulation. Multiple pair-wise BLASTn alignments and 
sequence alignment from the UCSC genome browser were used to identify two 
conserved regions within NAGS, which were determined to be a promoter and an 
enhancer. The efficacy of this method was confirmed by successful identification of the 
experimentally identified promoter and -6.3kb enhancer [46,47], along with three 
additional highly conserved regions, in the non-coding region upstream of CPS1. It 
should be noted that the high stringency of our BLASTn analysis (80% identity and at 
least 100bp of aligned sequence in four or more species) was selected to identify 
conserved regions that could support multiple binding sites where complexes of 
transcription factors may form [47,163]. This may have caused us to overlook species 
specific or isolated binding motifs, such as the recently identified FXR binding site [164].  
The reporter assay results confirm that the two highly conserved regions within 
1kb and 3kb upstream of the translational start site function as promoter and enhancer, 
respectively. The promoter activates expression of the luciferase reporter gene and we 
therefore infer that it will activate transcription of NAGS in vivo. Similarly, the enhancer 
in either orientation increases expression of luciferase by approximately 50% relative to 
the promoter alone, suggesting that it increases NAGS transcription as well. The relatively 
small but significant effect of the enhancer could be due to spacing differences between 
the genomic NAGS promoter and enhancer and their spacing in the reporter constructs. 
Alternatively, while HepG2 cells express transcription factors that we identified using 
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bioinformatic tools, the NAGS enhancer may bind additional factors, absent in HepG2 
cells, and have larger effect in vivo than in cultured cells. Another explanation for the 
relatively small effect of the NAGS enhancer is the possible presence of a proximal 
enhancer within the region we termed the promoter. Additional experiments are 
necessary to distinguish between these two possibilities.  
Our analysis of the NAGS transcriptional start sites identified multiple TSS that 
may be species and tissue specific. While the function of each TSS is unknown, these 
results are consistent with transcription initiation by Sp1 [57,165,166], and future 
experiments may find that they are involved in transcriptional control for tissue specific 
expression, developmental-stage specific expression, quantitatively different levels of 
mRNA expression, or may even determine the transcript stability [167].  
After we confirmed that the promoter and enhancer initiate and increase 
transcription, we looked for transcription factors that bind and regulate NAGS in these 
regions. By filtering for the highly over-represented and spatially conserved binding sites, 
relative to the translational start codon, we identified Sp1, CREB, and C/EBP in the 
promoter and HNF-1 AP-2, NF-Y, and SMAD-3 in the enhancer as transcription factors 
that could bind to the NAGS upstream region. This filtering method was confirmed by 
analysis of the -6.3kb enhancer of CPS1 in which binding sites for the previously 
published C/EBP, CREB, GR, and HNF-3 were identified.   
The protein-DNA pull down assays, designed to test which transcription factors 
among a pool of nuclear proteins bind to amplified sequence of conserved upstream 
DNA, confirmed that Sp1, CREB, HNF-1 and NF-Y bind to NAGS promoter and 
enhancer, while we could not detect binding of C/EBP, AP-2 and SMAD3 (Figure 9). We 
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initially used 60bp probes encompassing a specific binding motif for the protein–DNA 
pull down assays. However, probes encompassing the entire region were better able to 
bind transcription factors (data not shown), suggesting that binding is facilitated by 
interactions with DNA sequences outside predicted binding sites and possibly other 
transcription factors and co-activators. ChIP analysis was used to confirm binding of the 
predicted transcription factors to the DNA regions of interest under physiological 
conditions. ChIP and DNA-pull down assays confirmed that Sp1 and CREB bind to the 
promoter and HNF-1 and NF-Y bind to the enhancer of NAGS, while reporter assays 
demonstrated the functional importance of each binding motif by a decrease in 
transcription following mutagenesis of the binding sites (Figure 11).  
Furthermore, we have demonstrated that Sp1 and HNF-1 are important for 
stimulation of transcription of NAGS and that HNF-1 determines tissue specificity of 
NAGS expression. In the liver derived cell line, co-transfection of either Sp1 or HNF-1 
expression plasmids with reporter constructs containing the NAGS promoter and enhancer 
led to increased expression of the reporter gene (Figure 11) suggesting that these two 
transcription factors regulate expression of NAGS in the liver. In the lung and intestine 
derived cell lines, expression of HNF-1 was sufficient to activate expression of reporter 
gene in constructs containing NAGS enhancer and promoter (Figure 12). This suggests 
that HNF-1 binding to the NAGS enhancer determines tissue specificity of NAGS 
expression. Testing the effect of CREB protein was hindered by its capacity to homo- and 
heterodimerize with multiple partners [168,169]. The effect of NF-Y was not tested 
because this transcription factor is a complex heterotrimer [170] and its co-expression 
with reporter plasmids would require stable expression of NF-Y subunit proteins by in 
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vitro cell culture before reporter plasmids can be co-transfected and assayed for their 
effect on transcription.  
From the data provided herein, we can speculate on the potential role these factors 
play in regulating NAGS transcription. First, in the absence of a canonical TATA-box, 
transcription initiated by Sp1 often results in multiple transcriptional start sites [171,172]. 
Sp1 is a strong activator of transcription [57,173,174,175,176] and when multiple Sp1 
sites are present, as in NAGS, multiple Sp1 proteins can form complexes with each other 
and synergistically activate transcription [57,174]. Because transcription is significantly 
increased by co-expression with Sp1 protein and decreased following mutation of the Sp1 
binding sites, Sp1 may prove to be the activator of NAGS transcription, similar to its role 
for ASS, ASL and ARG1 [47,76].  
Second, studies have shown that glucagon and second messenger cAMP trigger a 
cascade that phosphorylates CREB and allows for DNA binding and activation of 
transcription [177,178]. In CPS1 and ASS, CREB stimulates transcription upon glucagon 
signaling [46,76]. Decrease in transcription following CREB binding site mutation and 
the close proximity of Sp1 and CREB binding sites among the TSS suggests that the 
transcription initiation machinery may be recruited by these factors, and future research 
should examine this postulate.   
Our experiments and other studies [95] confirm the role of HNF-1 in NAGS 
expression. HNF-1 is essential for stimulation of NAGS expression by its enhancer. This 
factor is in part regulated by HNF-3, HNF-4, and C/EBP, each of which are known to 
regulate other urea cycle genes [79,179,180]. Future research could focus on the 
mechanism of control between these factors, HNF-1, and NAGS. Our study has also 
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shown that NF-Y is an activator of NAGS expression, and future studies will focus on the 
exact mechanism of its function in this context.  
The human NAGS gene on the forward strand of chromosome 17 partially 
overlaps with the peptide YY (PYY) gene, which is on the reverse strand. This overlap 
was identified with a PYY cDNA isolated from a brain astrocytoma cDNA library that has 
an 80 nucleotide long exon located between regions A and B of the NAGS promoter 
[181,182] (Figure 3). Other full-length PYY transcripts initiate about 500 bp upstream of 
the PYY coding region, which is located 51 kb upstream of the NAGS translation 
initiation codon. Recent analysis of human transcripts revealed that many protein coding 
loci are associated with at least one transcript that initiates from a distal site [183], but the 
significance or function of these transcripts remains to be elucidated. Partial overlap 
between human NAGS and PYY genes raises the interesting possibility that these two 
genes share cis-acting regulatory elements and might be co-regulated [182,184]. The 
mechanism of co-regulation of human NAGS and PYY is likely to be complex because of 
their differing tissue expression patterns [42,185,186,187] including differing cell types 
within the intestine. PYY is expressed in the intestinal neuroendocrine cells [188,189] 
while enterocytes in the intestinal mucosa express NAGS [190,191], together with OTC 
and CPS1 [51,192]. Inspection of the transcription factor binding track of the UCSC 
genome browser revealed two binding sites for the CTCF transcription repressor between 
NAGS and PYY genes; they are located approximately 9.5 and 21 kb upstream of the 
NAGS coding region. The CTCF binding sites could act as chromatin insulators 
[193,194,195] and either block regulation of PYY by the NAGS enhancer or enable cell 
type specific regulation of each gene by the NAGS enhancer and promoter. Our results 
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show that the NAGS promoter in the reverse orientation does not activate transcription of 
the reporter gene in liver derived cells (Figure 5), but this does not preclude transcription 
activation in other cell types, not tested in this study. It is possible that the NAGS 
promoter, enhancer, or other NAGS region, regulates expression of PYY [187], and 
reporter assays in tissues and cultured cells which express PYY would test this hypothesis. 
While regulation of NAGS by Sp1, CREB, HNF-1, NF-Y, and factors that 
regulate them, requires additional study, identification of regions that regulate human 
NAGS and OTC have enabled diagnosis of patients with clinical symptoms of urea cycle 
disorders, but lacking disease causing mutations in the coding regions of the genes 
[95,196]. Recently, we identified a patient with a mutation in the enhancer of NAGS and 
confirmed the diagnosis of NAGS deficiency by showing that the mutation significantly 
decreases transcription of NAGS [95]. This example suggests that identification of 
regulatory regions within genes will lead to more and better diagnoses of urea cycle 
disorders and other genetic diseases and to accurate genetic counseling. 
In conclusion, this study identified a promoter and a tissue specific enhancer of 
NAGS and functionally relevant transcription factor binding motifs within these regions.  
The results show that Sp1 and CREB bind to the NAGS promoter, suggesting that 
glucagon and cAMP signaling may regulate the expression of NAGS. Within the 
enhancer, HNF-1 may be an important factor in the coordinated regulation of this urea 
cycle gene transcription through its interaction with HNF-3, HNF-4 and C/EBP while the 
role of NF-Y is less clear considering that NF-Y may function as an activator or 
repressor. While additional studies will be needed to further define the roles of these 
factors, these results contain the first thorough analysis of NAGS and suggest networks of 
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control between signaling cascades, NAGS and the coordinated regulation of the other 
urea cycle genes.   
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Introduction 
The urea cycle requires the coordinated function of 6 enzymes and 2 
mitochondrial membrane transporters to convert ammonia into urea [197]. An 
interruption in any step of the urea cycle can lead to hyperammonemia, and may result in 
brain damage, coma and death [197]. 
The initial step of the urea cycle is catalyzed by carbamyl phosphate synthetase I 
(CPS1) (EC 6.3.4.16), generating carbamyl phosphate from ammonia, bicarbonate and 
ATP. However, CPS1 is only active in the presence of its allosteric activator, N-
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acetylglutamate (NAG), biosynthesized by N-acetylglutamate synthase (NAGS; EC 
2.3.1.1) from glutamate and acetyl-coenzyme A.  
Biochemically, a deficiency of NAG, as observed in inherited NAGS deficiency 
[198] (MIM #237310), is indistinguishable from CPS1 deficiency (MIM #237300), as 
both conditions result in hyperammonemia due to reduced flux through the CPS1 
enzyme. Initial diagnoses of NAGS deficiency were based on measurements of hepatic 
NAGS activity [198,199], though these assays may not be entirely reliable [101,200,201]. 
The cloning of the human NAGS gene (MIM #608300) in 2002 [42] has allowed 
molecular testing to become the primary method of diagnosis. Mutations in the coding 
region of the NAGS gene have been identified in all reported cases of NAGS deficiency 
since 2002 [97,99,105,106,114,116,117,202].  
Patients with NAGS deficiency respond remarkably well when administered N-
carbamylglutamate (NCG), a stable structural analog of NAG, which has been shown to 
activate CPS1 in vitro [203], normalize blood ammonia [116,204], and restore 
ureagenesis [116,204]. In fact, NAGS deficiency is the only urea cycle disorder (UCD) in 
which urea cycle function may be restored through a pharmacological agent. In other urea 
cycle disorders, medical treatment is suboptimal, and consists of dietary protein 
restriction and ammonia scavenging agents [109]. 
The regulatory regions of the NAGS gene were recently identified [44] NAGS 
transcription is regulated by a promoter, which contains multiple Sp1 (Specificity protein 
1) and one CREB (cAMP response element binding) binding sites, and an enhancer 3kb 
upstream of the coding sequence to which HNF-1 (Hepatic Nuclear Factor 1) and NF-Y 
(Nuclear factor Y) bind.  
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Mutations within the regulatory regions of genes currently represent a very small 
proportion of known disease causing mutations [205], and are likely underdiagnosed. 
Indeed, there has been only one report of a disease-causing mutation in a regulatory 
region of a urea cycle gene [196].  
In this report, we describe the first NAGS enhancer mutation, identified in a 
patient with an unspecified proximal urea cycle disorder, who despite the absence of any 
identifiable NAGS mutations by conventional mutation analysis [99,206], demonstrated a 
marked response to a short-term trial of NCG. We demonstrate that the mutation 
ascertained in our patient is indeed deleterious, and results in decreased transcription 
factor binding and expression of the NAGS gene. We also document the patient’s 
favorable subsequent response to chronic treatment with NCG, leading to apparent 
normalization of her health. 
Materials and Methods 
Case Report 
The patient was a 17-year-old girl of Eastern European origin, with an unspecified 
proximal urea cycle disorder. At 10 years of age, she presented to the Emergency 
Department with a 3-day history of nausea, ataxia, and somnolence. Initial plasma 
ammonia was 203 µM, anion gap 13, glutamine 868 µM, citrulline 12 µM, BUN 3.6 mM. 
She was tentatively diagnosed with partial OTC deficiency, however, a subsequent 
allopurinol challenge revealed normal orotic acid excretion in response to the drug, 
making this diagnosis improbable. In addition, sequencing of exons and intron/exon 
boundaries for NAGS, CPS1 (MIM #608307) and OTC (MIM #300461) did not reveal 
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any pathogenic mutation. In a further attempt to reach a diagnosis, a liver biopsy was 
performed, but enzymatic analysis of hepatocyte CPS1 and OTC demonstrated normal 
activity. Analysis of hepatic NAGS enzyme activity was not performed. Because of the 
succession of non-diagnostic investigations, we considered enrolling her into a short-term 
clinical trial of N-carbamylglutamate (NCG) [116,204]. We deemed that a diagnosis of 
partial NAGS deficiency was still plausible, and that a short-term treatment with NCG 
might not only be diagnostic, but would also correct the metabolic defect in this 
condition, as observed in previous studies [116,204,205]. In addition, a short-term trial 
was not likely to be harmful in the other proximal urea cycle disorders. Indeed, a partial 
CPS1 deficiency might in fact respond to supraphysiological levels of a CPS1 activator 
[207,208]. We discussed an NCG trial with the patient and her parents, and they 
consented to the study. 
N-Carbamylglutamate study 
The study design (Figure 13) has been used in our prior NCG studies [116,209]. 
As shown, the patient underwent an identical study procedure before and immediately 
following treatment for 3 days with oral NCG (Carbaglu, Orphan Europe, Paris, 
2.2g/m2/d in four divided doses). The study was carried out by Dr. Nicholas Ah Mew and 
was approved by the Children’s National Medical Center Institutional Review Board with 
informed consent was obtained before enrollment. 
On day 1 of the clinical study, an indwelling venous catheter was used for blood 
drawing. On day 4, however, peripheral intravenous access could not be obtained, and a 
peripherally inserted central catheter (PICC) was introduced. The PICC remained in place 
for the remainder of the study, and was removed upon obtaining the last blood sample. 
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Following an overnight fast, a baseline sample (5 mL) of heparinized blood was 
obtained (time 0). Then, the subject ingested 0.33 mmol/kg, (27.5 mg/kg) of [1-13C] 
sodium acetate (98 atom % excess) dissolved in 60 mL of water. Blood samples (4 mL) 
were subsequently obtained at 15, 30, 45, 60, 90, 120, 180, and 240 minutes, and drawn 
into a pre-cooled, heparinized tube. The sample was immediately centrifuged at 4°C to 
separate the plasma, which was directly transferred to cryogenic tubes, placed in dry ice, 
and kept frozen at -70°C until analysis, performed within 2 days after collection, as 
previously described [116,210]. Each sample was analyzed for plasma ammonia and urea 
(RXL Dade Behring, Siemens Healthcare Diagnostics, Deerfield, IL), quantitative amino 
acids (Biochrom, Cambridge, UK), and [13C]urea [116,210]. 
Mutation Detection 
The patient’s NAGS gene was amplified using primers listed in Table 11. 
Polymerase Chain Reaction (PCR) conditions were: 3m initial denaturation at 98°C, 
followed by 30 cycles of 30s denaturation at 98°C, 30s of annealing at 65°C, 50s 
extension at 72°C, and final extension of 5m at 72°C. The entire NAGS gene, from 3.5kb 
upstream of the start codon to 250bp downstream of the termination codon, including 
introns, was amplified and sequenced. Two small regions from c.-1414 to -1346 (68bp) 
and c.2301 to 2575 (274bp), could not be sequenced likely due to the GC-rich nature of 
these segments. These two segments fall within a non-conserved 5’-untranscribed 







Figure 13. Experimental time line.  
Identical studies were performed before and immediately following a 3-day course of 
NCG at a dose of 2.2 g/m2/d. Plasma samples for ammonia, urea, amino acids, and 
[13C]urea were obtained at 0, 15, 30, 45, 60, 90, 120, 180, and 240 minutes prior (time 0) 




 The patient’s parents’ NAGS enhancers were also sequenced using forward 
primer hNAGS-Enh 5’-CTGAACCTGGGCACAATGACAACA-3’, and reverse primer 
hNAGS-Enh 5’-TATGAGGTGGAAATGGGCTGGGAA-3’. The genomic DNA from a 
healthy individual was used as a control. The NM_153006.1 
(www.ncbi.nlm.nih.gov/nuccore) sequence of the human NAGS gene was used as 
reference for sequence comparisons.  
SNP Genotyping 
Genotyping was completed using TaqMan allele discrimination assays from 
Applied Biosystems Inc. according to the manufacturer's instructions (See Table 12 for 
the PCR primers and allele specific probes). The end point fluorescent readings were 
performed on an ABI 7900HT Sequence Detection System (SDS V 2.3 software; Applied 
Biosystems).  For quality control, negative controls and duplicate samples (100% 
agreement) were included in the analysis.    
Consensus sequence of HNF-1 Binding Motif 
A consensus binding site for transcription factor HNF-1 was determined based on 
similarity matrices M01011, M00790, M00206, and M00132 in the TRANSFAC 
database (Figure 14A) [211,212,213,214,215]. At sites with ambiguous nucleotide 
identity, selection of nucleotide deferred to human NAGS. The consensus binding site for 













f-forward and r-reverse 
 
Name Sequence 
Tile1-1f 5- GTG ACT GTG GCT GGT GTG GGT CTC C -3 
Tile1-1r 5- GCC AGC TCT TCA TCA CAG CAG GCC ACC -3 
Tile 2-1f 5- GAT ACC AGT CCT GCC CTC AGG GAG CC -3 
Tile2-1r 5- CAG GGT CAC TCA GCT CAC AAG CCG TGG -3 
Tile3-1f 5- GGGTCT GGC CAT GCC ACT GAC GAG C -3 
Tile3-1r 5- GTG AGG AGG CGG GTG GGT CAT TTG AGG -3 
Tile4-2f 5- AGG TTA AAG AGG GCC GGG CGT GGT GG -3 
Tile4-2r 5- GGG TGG TGC TGG CCT TGT CTG TCC TG -3 
Tile5-2f 5- GTC TGG GCA ACA TGG TGA ACA CCC GTC -3 
Tile5-2r 5- CAG AAC CAC AGC CAT CAG CGC CGT C -3 
Tile6-2f 5- CGA CGG CGC TGA TGG CTG TGG TTC TG -3 
Tile6-2r 5- CCG TCT CGG TGA CCC TAC CCT TCC AG -3 
Tile7-2f 5- CCA TCA CTC CGC GGA CAA GCC CTT CG -3 
Tile7-2r 5- CGG GCA GAG TAG CAC GCT CTG AGG AC -3 
Tile8-2f 5- TTT GGC GGC GGG TCT GTG CTA CG -3 
Tile8-2r 5- TCC TGG ACA GGA GGA GAA GCC GC -3 
Tile9-1f 5- CCC ACC ACT CCT CGG CCG TCA TCA CC -3 
Tile9-1r 5- CCT TGG TCC GAA GCT GCC CGA CTG CCC -3 
Tile10-1f 5- GGG ACG ACT ACC TGG CCT CGC TG -3 
Tile10-1r 5- GAG GAC CTA CTG CAT GCT GGG CAC C -3 
Tile11-1f 5- CCC ACG CAG CCC ACC TCT CAC AG -3 
Tile11-1r 5- CCT GAG TAG AGC CCT GGA AGG CAC CC -3 
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Table 12. TaqMan primers and probes used for SNP genotyping. 
Mutation Forward Primer Reverse Primer Common allele probe (5' VIC) 














Figure 14. Sequence alignments.  
(A) The human NAGS HNF-1 binding site and matrices for HNF-1 binding sites from the 
TRANSFAC database and indication of the c.-3064C>A mutation. (B) Reference 
mammalian DNA sequence of the HNF-1 binding site was aligned with the patient’s 
HNF-1 binding site.  The c.-3064C>A mutation (box) is indicated. Standard nucleotide 




The c.-3064C>A patient mutation and c.-3069C>A, c.-3066C>T, c.-3065T>A, 
c.-3061C>A consensus HNF-1 binding site mutations were engineered into the NAGS 
gene using QuickChange Lightening Site-Directed Mutagenesis Kit (Agilent) according 
to manufacturer’s instructions. Primers NAGS c.–3064C>A Fw and Rv (Table 13) 
amplified 100ng of template plasmid 4.10Enh [44] to create 4.10EnhPat. Amplification 
of 100ng of 4.10WT using primers NAGS HNF-1con Fw and Rv (Table 13) created 
4.10EnhCon plasmid. The presence of each mutation was confirmed by 
sequencing. Cloning of wild-type and mutated NAGS enhancers into plasmids for 
analysis of transcription is described in detail in the previous chapter.   
Tissue Culture and Reporter Assays 
Cell culture and transfections  
Human hepatoma cells (HepG2) (donated by Dr. Marshall Summar, Children’s 
National Medical Center, Washington, DC) were cultured in complete media containing 
RPMI 1640 supplemented with 10% FBS (fetal bovine serum) and 5% 
Penicillin/Streptomycin under 5% CO2 at 37°C.  Cells were plated at a density of 5 x 105 
cells/well on 24-well culture plates 24 hours prior to transfection.  The cells (90% 
confluent) were then transfected using Lipofectamine 2000 (Invitrogen) and cultured in 
transfection media containing RPMI 1640 supplemented with 10% FBS.  Cells were 
transfected with reporter plasmids 4.10WT, 4.10Pat, 4.10Con, 4.23WT, 4.23Pat, or 
4.23Con, described in the electronic supplement, or control plasmids (Table 14). A total 
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of 0.25 µg of DNA was co-transfected with 0.225 µg of luc2 containing expression 
vector and 0.025µg of transfection control vector pGL4.74.   
Reporter Assays 
24 hours following transfection, cells were assayed for both firefly and Renilla 
luciferase activity using Dual-Luciferase Reporter Assay System (Promega) and 
Berthold Centro 960 luminometer (Berthold) according to the manufacturer’s protocol.  
All reporter assay values were corrected for transfection efficiency by normalizing the 
firefly luciferase signal to the Renilla luciferase values. Mean values are expressed 
relative to wild-type and calculated error was from three trials and reported as ± standard 
error of the means (SEM).  To evaluate the effects of enhancer and promoter from 
repeated measurements over three series of experiments, mixed-effects linear regression 
(Stata 10) was employed. 
Avidin-Agarose DNA-Protein Pull-Down Assay 
Biotinylated DNA probes 
Biotinylated and non-biotinylated probes for the enhancer region of human NAGS 
were amplified from genomic DNA isolated from donated mouse tail using Pure Gene 
DNA Purification Kit (Gentra) or 4.10EnhPat and 4.10EnhCon plasmids with primers in 
Table 15 and conditions as described previously [44]. Resulting probes were referred to 





Table 13. Primers used to generate c.-3064C>A and consensus HNF-1 binding site 
mutants via site-directed mutagenesis. 
Primer Name Primer Sequence 
NAGS-3064C>A FW 5’-GGCCTGGAGTTAATCATCTAATCTGGTATCTCTGG-3’ 
NAGS-3064C>A RV 5’-CCAGAGATACCAGATTAGATGATTAACTCCAGGCC-3’ 
NAGS HNF-1con Fw 5’-CCAGGGTCAATGGGCCTGGAGTTAATAATTAACTATG 
GTATCTCTGGGCC-3’ 




Table 14. Plasmids for reporter assays with promoter, enhancer and reporter genes 
as indicated.  
Plasmid Enhancer Promoter Reporter Gene 
pGL4.10WT NAGS NAGS luc2 
pGL4.10Pat c.-3064C>A NAGS  NAGS luc2 
pGL4.10Con Consensus NAGS NAGS luc2 
pGL4.23WT NAGS TATA-box luc2 
pGL4.23Pat c.-3064C>A NAGS  TATA-box luc2 
pGL4.23Con Consensus NAGS TATA-box luc2 
pGL4.10 - - luc2 
pGL4.13 - SV40 luc2 
pGL4.23 - TATA-box luc2 
pGL4.74 - HSV-TK hRluc 
Reporter genes were from Photinus pyralis (luc2) and Renilla reniformis (hRluc). 
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Preparation of nuclear extracts 
Nuclear extract was isolated from donated adult mouse livers of C57BL/6 mice 
using Nuclear Extraction Kit (Origene) according to manufacturer’s instructions.  The 
protein concentration of the nuclear extract was determined using Bradford Assay dye 
concentrate reagents (Bio-Rad, Hercules, CA).  On average 10mg of nuclear protein was 
obtained from one mouse liver. 
Binding Protocol 
The binding assay was carried out as described in the previous chapter.   Briefly, 
nuclear extract was incubated with 15 µg of the DNA probe for 16 hrs at 4°. Following 
incubation, the beads were washed and resuspended in denaturing buffer. The proteins 
were resolved on SDS-PAGE, transferred to a nitrocellulose membrane, and identified 
by immunoblotting using primary antibodies against HNF-1α/β at 1:500 dilutation and 
NF-Yα at 1:1000 dilution (Santa Cruz Biotech) and HRP conjugated secondary donkey 
anti-rabbit antibody at 1:20,000 dilutation (Pierce) The bands were visualized using 
SuperSignal West Pico Kit (Pierce) according to manufacturer’s instructions.  Band 
intensity was measured using GS-800 Calibrated Densitometer (Bio-Rad and Quantity 
One 1-D Analysis Software (Bio-Rad). Values were expressed as mean ± SEM and 
analyzed using Student’s t-test. 
Results 
N-carbamylglutamate trial 
The stable isotope method for measuring in vivo ureagenesis has been previously 
applied to assess ureagenesis in normal unaffected individuals [116], as well as to 
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evaluate response to a 3-day trial with NCG in patients with NAGS deficiency and 
propionic acidemia [116,209]. Figure 15 summarizes the results of the tracer study 
before and at the end of the 3-day treatment with NCG. In the described patient, the pre-
treatment production of [13C]urea attained a peak of only 0.017 atom % excess (Fig 
15A). Therapy with NCG for 3 days augmented this parameter over 7-fold to 0.12 atom 
% excess. Correspondingly, peak blood [13C]urea concentration before administration of 
NCG was 0.074µM, and 2.0µM, following treatment, a remarkable 27-fold increase 
above baseline (Fig 15B). In comparison, the peak concentration of this parameter in 38 
untreated adult control studies was 4.01±0.59 µM (mean±SEM) [116].  
This marked increase in nitrogen disposal was corroborated by changes in other 
biomarkers, as illustrated in Table 15. Ammonia at baseline was normal at 21 µM, and 
remained essentially unchanged at 18 µM following therapy. However, blood Urea 
Nitrogen (BUN) increased over three-fold (Table 15) and mean glutamine and alanine 





Figure 15. Isotopic enrichment of [13C]urea.  
Increase over time in isotopic enrichment of [13C]urea (A) and plasma concentration of 
[13C]urea (B) in the patient, who was administered 27.5 mg/kg of [1-13C]sodium acetate 




Table 15. Plasma ammonia, urea, glutamine and alanine (mean ± SD) in the patient 
before and after 3 days treatment with NCG. 
Biomarker Pre-NCG Post-NCG 
Ammonia (µmol/l) 21 ± 6 18 ± 3 
Urea (mmol/l) 0.4 ± 0.1 1.4 ± 0.1 
Glutamine (µmol/l) 553 ± 61 309 ± 29 





Mutation detection and SNP Genotyping 
Sequencing of the patient’s NAGS gene, from 3.5kb upstream of the translation 
start codon to 250bp downsteam of the termination codon, revealed 16 homozygous and 
1 heterozygous sequence alteration compared to the reference NAGS sequence from the 
NCBI database. All but one were identified as commonly-occurring polymorphisms in 
dbSNP (build 132: http://www.ncbi.nlm.nih.gov/SNP/) [216], or were also present in the 
wild-type control sequence. The remaining change, a homozygous C to A transversion 
3064bp upstream of the NAGS translation start codon (c.-3064C>A) (Figure 16), was 
determined to be in the recently identified hepatic nuclear factor 1 (HNF-1) binding site 
of a conserved NAGS regulatory region (Figure 17) [44]. The patient’s parents were both 
heterozygous for this change.  
While the mutated cytosine nucleotide is completely conserved among 7 
mammalian species (Figure 14), single nucleotide polymorphism (SNP) genotyping was 
conducted to determine whether the c.-3064C>A change could be an uncommon change 
found in the general population. The mutation was not detected in 1086 control alleles 
(Table 16), with representation of the patient’s ethnic origin. The diverse cohort of 
subjects obtained through the Human Genome Diversity Panel (HGDP) [217] included 
36 individuals from Russia, 150 subjects from Asia including Japan, China Cambodia, 
and Papua New Guinea, 56 subjects from South America including native Mexicans and 
Columbians, and 36 subjects from Western Africa including Nigeria and Senegal, and 




Figure 16. DNA sequence of the HNF-1 binding site within the enhancer of the 
NAGS gene.  
The patient is homozygous for a single base substitution at position -3064. The patient’s 
parents are heterozygous for this allele at the same position. Highlighted base indicates 





Figure 17. Transcription factor binding sites in the NAGS enhancer.  




Table 16. Allele frequencies in populations analyzed by SNP genotyping. 
  Genotype 
  CC CA/AA 
Number of Screened Individuals N=543 N=543 
Russian 36 0 
Northern European 265 0 
South American* 56 0 
Asian+ 150 0 
Ethnicity 
Western African† 36 0 
*Subjects were native Mexican and native Columbian 
+Subjects were Japanese, Cambodian, Papau New Guinean, and Chinese 






The functional effect of the mutation on NAGS transcription was examined using 
a luciferase reporter assay, driven by the NAGS enhancer with either the wild-type, 
mutated, or consensus HNF-1 binding sites. Reporter plasmids included the NAGS wild-
type promoter with the wild-type enhancer, 4.10WT, the enhancer containing the 
patient’s mutation -3064C>A, 4.10Pat, or the enhancer containing the consensus HNF-1 
binding site, 4.10Con (Figure 18A). Additional reporter plasmids included a minimum 
TATA–promoter and the wild-type enhancer, 4.23WT, the enhancer containing the 
patient’s mutation, 4.23Pat, or the consensus enhancer, 4.23Con (Figure 18B) to isolate 
the role of the enhancers. HepG2 cells were transfected with the reporter plasmids or 
pGL4.10, pGL4.13, and pGL4.23 as negative, positive, and reference controls 
respectively. Cells were co-transfected with vector pGL4.74, containing Renilla 
luciferase hRluc, as a transfection efficiency control.   
 Transcription of luciferase was decreased by 25% in cells transfected with 
plasmids harboring the -3064C>A mutation, compared to the wild-type enhancer, and 
either the NAGS or TATA-containing promoter (4.10Pat p<0.001 , 4.23Pat p<0.001) 
(Figure 18A & B). Transcription of luciferase increased in cells transfected with 
plasmids containing the consensus enhancer, compared to wild-type, and either promoter 
(4.10Con, 35% greater, p<0.001, 4.23Con, 75% greater, p=0.006 ) (Figure 18A & B). 
No luciferase expression was detected for each enhancer alone, in the absence of a 
promoter (data not shown). Control vectors pGL4.10 and pGL4.23 did not stimulate 
luciferase expression while positive control vector pGL4.13 activated transcription in 
this cell culture system as previously shown [44]. Measured luciferase activity was 
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normalized to hRluc expression to adjust for transfection efficiencies. Statistical analysis 
was performed for normalized values while graphical representation is displayed as 
normalized values relative to the selected promoter with the wild-type enhancer. The 
reporter assay results compared to wild-type, showed an increase in transcription of 
luciferase when the consensus HNF-1 binding site was present and a decrease when the 
wild-type HNF-1 binding site contained the c.-3064C>A mutation. 
Pull-Down Assays 
To examine the direct effect of the mutation, a DNA-protein pull-down assay 
was devised in which biotin-labeled DNA probes containing the wild-type (pWT), c.-
3064C>A mutation (pPat), and consensus (pCon) HNF-1 binding site were incubated 
with nuclear proteins, precipitated using avidin-agarose beads, and analyzed by 
immunoblot.  
The biotinylated enhancer probes pWT, pPat, and pCon contained 333bp of the 
NAGS sequence from c.-2834 to -3167 (Figure 19B, lanes 1, 3, and 5). Non-biotinylated 
enhancer probes were used as negative controls (Figure 19B, lanes 2, 4, and 6). 
Normalized results showed a 30% increase in band intensity for pCon (p=0.015) and a 
40% decrease in band intensity for pPat (p=0.001) compared to pWT (Figure 19A). 
Negative control DNA probes did not bind HNF-1 (Figure 19B, lanes 2, 4, and 6).  
These results indicate that HNF-1 binding is reduced in the presence of the c.-3064C>A 





Figure 18. Effects of the c.-3064C>A mutation and consensus HNF-1 binding site on 
gene expression.  
Luciferase expression is significantly different between wild-type, -3064C>A, and 
consensus enhancers when expressed in conjunction with the human wild-type NAGS 
promoter (A) or the minimal TATA-box promoter (B). All results are an average of three 
independent experiments that were each carried out in triplicate. Calculated error was 
from three trials and reported as ±SEM. One asterisk (*) indicates p<0.05 and two 






Figure 19. Effects of the -3064C>A mutation and consensus HNF-1 binding site on 
pull-down of HNF-1 protein.  
Amounts of HFN-1 protein pulled down were significantly different between enhancers 
containing the wild-type, c.-3064C>A mutated, or consensus HNF-1 binding site (A). 
Immunoblots (B) show HNF-1 and NF-Y protein following overnight incubation with 
whole nuclear extract. Values are normalized means from three replicate experiments. 
Immunoblots are representative of the results obtained by three replicate experiments. 
Calculated error was from three trials and reported as ±SEM. One asterisk (*) indicates 
p<0.05 and two asterisks (**) indicate p<0.005. 
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Chronic Therapy with N-carbamylglutamate 
Given the substantial experimental evidence that the patient’s mutation was 
deleterious, as well as her marked response to a short-term trial of NCG, she was 
prescribed daily NCG treatment. 
On her clinic visit just prior to NCG administration, plasma ammonia level was 
118µM, glutamine 601µM, alanine 579 µM, blood urea nitrogen 0.7 mM, and arginine 
25 µM. Also, essential amino acids, including branched chain amino acids, were low, 
presumably as a result of protein restriction and alternate pathway therapy. At the time 
her dietary protein consumption was limited to 0.5g/kg/d (~30-35g/d), and she was on 
sodium phenylbutyrate at 18g/day.  
We prescribed a continuous daily regimen of oral NCG, 2.2 g/m2/d, identical to her dose 
during the short-term trial. Phenylbutyrate intake was tapered off over a month, and the 
patient has been able to entirely liberalize her dietary protein. During the three months of 
therapy to date, she has been clinically well. Her most recent plasma ammonia level was 
4 µM, glutamine 379 µM, alanine 374 µM, and arginine 105 µM. Blood urea nitrogen 
was 4.6 mM, the highest ever recorded in her. 
Discussion 
This is the first report of a disease-causing mutation in the regulatory region of 
NAGS and the second in any urea-cycle gene [196]. NAGS deficiency is the rarest of the 
urea cycle disorders [93]. In the 2008 report from the Urea Cycle Disease Consortium 
Longitudinal Study, there were no enrolled patients with NAGS deficiency [93], yet 
there were 11 patients without a current specific diagnosis that had symptomatic 
hyperammonemic episodes and biochemical measures highly suggestive of a urea cycle 
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disorder (UCD). It is likely that these patients have proximal UCDs since distal UCDs 
and transporter defects typically present with additional amino acid abnormalities. These 
undiagnosed patients may in fact have mutations in the regulatory region of NAGS or 
CPS1 genes. 
 Although it is well documented that mutations in non-coding regions of a gene 
can result in disease [219,220,221], currently available clinical molecular diagnostics 
frequently do not screen for mutations in regulatory regions, and therefore such patients 
are likely to remain undiagnosed. In a recent report from the Human Genome Mutation 
Database (HGMD, www.hgmd.cf.ac.uk) [205], only 1.6% of all reported mutations were 
in regulatory regions of genes. As a preliminary survey, we searched the public version 
of HGMD for apparently regulatory mutations in the 8 genes of the urea cycle as well as 
the genes of the American College of Medical Genetics newborn screening core panel, 
not including congenital deafness, cystic fibrosis or the hemoglobinopathies. As of 
March 10, 2011, this search only identified a single (aforementioned) disease-causing 
regulatory mutation in the OTC promoter [196], out of 3316 reported mutations in genes 
associated with inherited metabolic disease.  
In the patient described herein, with a high clinical suspicion of NAGS 
deficiency, a successful diagnostic strategy involved sequencing nearly the entire NAGS 
gene, including the upstream regulatory regions. Continued advances in molecular 
genetics have allowed for more rapid and accurate sequencing of vast regions of DNA. 
These technologies will be applied to sequence not just exons, but entire genes, in an 
attempt to identify deleterious mutations in other patients with a highly-likely clinical 
diagnosis. However, this strategy will certainly identify numerous single base 
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substitutions, and subsequent SNP genotyping, as well as functional studies, will be 
required to differentiate between common polymorphisms and disease causing 
mutations.  
In our SNP genotyping studies, our patient’s mutation was not identified in 1086 
control alleles, from individuals of varied ethnic backgrounds. Also, the patient’s parents 
were both heterozygous for the c.-3064C>A substitution, consistent with the autosomal 
recessive inheritance. These results were highly suggestive that the patient’s mutation 
was indeed deleterious. 
Functional studies ultimately determined the deleterious effect of the HNF-1 
binding-site mutation. While the role of HNF-1 in NAGS regulation is not yet entirely 
understood, these studies demonstrate that it plays an important role in the regulation of 
NAGS expression. The engineering of a consensus HNF-1 sequence resulted in increased 
HNF-1 binding (Figure 18). It is this enhanced affinity to HNF-1 that likely resulted in 
increased transcription of our reporter gene (Figure 18).  Conversely, the c.-3064C>A 
mutation results in decreased binding of HNF-1 (Figure 19), and thus significantly 
reduces, but does not abolish transcription (Figure 18).  
This patient, like others with regulatory mutations in genes coding for enzymes 
[196,222], presented at an age well after the neonatal period. This likely reflects the 
nature of promoter or enhancer mutations, which might decrease but not eliminate 
expression of the genes they regulate. The residual gene expression and enzymatic 
activity retained in these patients results in a less severe clinical presentation.  
Treatment with NCG is the therapy of choice in patients with NAGS deficiency, 
as it corrects the metabolic defect in this condition. In affected patients, NCG has been 
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shown to normalize blood ammonia [97,98,113,116,223] and restore ureagenesis [116]. 
This is likely the case in our patient, who has been symptom-free while on NCG, despite 
discontinuing ammonia scavengers and liberalizing protein in her diet. NCG may also 
have a salutary effect in other conditions where hepatic NAG is reduced [224], as well as 
in some patients with partial CPS1 deficiency [207,208]. 
In the short-term N-carbamylglutamate trial, we used a stable isotope method to 
assess in vivo changes to patients’ capacity for ureagenesis in response to NCG. Stable 
isotopes are safe, and in this case, the analysis of isotopic enrichment in blood urea, by 
ion-ratio mass spectrometry, is highly sensitive, robust and reproducible [225,226]. This 
method reliably documented the augmentation in ureagenesis following NCG 
administration in previous 8 patients studied by our group, including seven patients with 
propionic acidemia and one with NAGS deficiency [116,209]. In the previously-
described patient with NAGS deficiency, there was a greater than 4-fold increase in 13C 
label incorporation into urea following NCG administration – a marked augmentation 
that was also observed in the patient described herein. In fact, in this patient, this 
restoration of ureagenesis provided an important diagnostic clue, and triggered an 
extensive mutation search in the NAGS gene, culminating in the identification of the 
deleterious mutation and confirmation of the regulatory function of the site affected by 
it. This marked increase in isotope-enriched urea following a trial of NCG is likely 
pathognomonic of NAGS deficiency, and may be a useful diagnostic tool in future 
patients where this diagnosis is suspected, but in whom no deleterious mutations are 
identified. Furthermore, subsequent long-term treatment with NCG appears to have 
corrected the metabolic defect in our patient, suggesting that the increase in ureagenesis 
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observed during a short-term trial with NCG is predictive of the long-term response to 
this medication.   
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Introduction 
Within the liver, the urea cycle converts ammonia, a neurotoxic product of protein 
catabolism, into non-toxic urea, which is easily excreted in the urine [227]. The second 
enzyme in the cycle, ornithine transcarbamylase (OTC; EC 2.1.3.3), is a mitochondrial 
enzyme that catalyzes the formation of citrulline from ornithine and carbamylphosphate. 
The human OTC gene is 73 kb long and has ten exons, which contain a 1062 bp long 
coding sequence [228]. The human OTC protein is 354 amino acids long with a 32 amino 
acid mitochondrial targeting peptide at its N-terminus [229,230]. The human OTC 
protein is a homotrimer with three active sites, each shared between two adjacent 
monomers [231].  
OTC deficiency (OTCD) accounts for one-half of all urea cycle disorders [121] 
and is caused by mutations in the OTC gene that lead to reduced or absent functional 
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OTC enzyme. Because the human OTC gene is located on the X-chromosome, OTCD 
affects primarily hemizygous males and while the true prevalence of OTCD is unknown, 
it has been estimated to afflict approximately 1 in 14000 [91,119]. Severity and onset of 
disease in males varies due to mutation as mutations that severely impair OTC function 
manifest OTCD within the first five days of life [122] while mutations that reduce OTC 
activity or abundance may present clinically at any time after the first week of life 
[123,232]. Female carriers of these mutations may exhibit symptoms of OTCD later in 
life due to skewed lyonization [122,123]. The toxic effects of ammonia yield clinical 
symptoms of OTCD that include lethargy, vomiting, behavioral and neurological 
abnormalities, and, in severe cases, coma and death [233]. Biochemical abnormalities 
include high plasma ammonia, elevated plasma glutamine, low or absent plasma 
citrulline, and increased excretion of orotic acid and orotidine in the urine [227].  
OTC is expressed in the liver and intestine of humans and other mammals [227]. 
Transcription of the human OTC gene appears to initiate at multiple transcription start 
sites (TSS) [196], while transcription of the mouse and rat Otc genes initiate at 136 bp 
and 98 bp upstream of the translation initiation codon, respectively [234,235]. Four 
regions within the rat Otc promoter, A through D, bind transcription factors that regulate 
expression of the Otc gene [51]. Region A seems to negatively regulate transcription 
[51], but transcription factors that bind to this region have not been identified. Regions B 
and C bind transcriptional activator hepatocyte nuclear factor 4 (HNF4), and repressor 
chicken ovalbumin upstream promoter – transcription factor (COUP-TF) [51,55]. Region 
D is located downstream of the transcription start site and its role in expression of the Otc 
gene remains to be elucidated [51]. 
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Studies in transgenic mice determined that the rat Otc promoter was sufficient to 
direct expression of transgenes in the liver and intestine of transgenic mice, with higher 
expression in the intestine [49,143]. Expression studies in cultured cells and transgenic 
animals revealed that an enhancer, located approximately 11 kb upstream of the first exon 
of the rat Otc gene, is essential for a high level of expression of the Otc gene in the liver 
[51]. In vitro binding studies revealed four sites, designated I-IV, that are important for 
function of the -11 kb enhancer [51]. Transcription factors CCAAT enhancer binding 
protein (C/EBP), which binds to sites I and II, and HNF4, which binds to sites I and IV, 
activate expression of the Otc gene [72,73,236].  
While most cases of OTCD are caused by mutations in the exons or at the 
intron/exon boundaries of the OTC gene [123], some patients exhibit large deletions or 
insertions which interfere with the open reading frame or processing of the OTC mRNA 
and lead to absence of functional OTC [232,237,238,239,240,241,242,243]. Some 
mutations in the introns of OTC have created cryptic splice sites and resulted in defective 
mRNA [241,244]. Many molecular causes of OTCD have been accounted for in these 
regions, and to date a single mutation in the OTC promoter in one family resulted in late 
onset OTCD [196]. However, it is important to note that a significant proportion of 
patients with clinical OTCD still lack the molecular cause of the disease [123].  
The first goal of this study was to determine whether OTCD patients lacking an 
identified molecular cause of the disease have a deleterious mutation in the 5’ flanking 
region of the OTC gene. To that end, we identified a group of patients with clinically 
diagnosed OTCD, but no disease-causing mutations in the coding region or intron/exon 
boundaries and then identified two new mutations in the HNF4 binding site in the 
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promoter of the OTC gene that reduced transcription factor binding in three patients. The 
second goal was to evaluate the feasibility of identifying disease-causing mutations 
outside of the coding regions and splice junctions of genes without extensive functional 
tests. Through bioinformatic analyses and SNP genotyping, we identified disease-causing 
mutations in the regulatory regions of OTC. These methods will lead to improved 
diagnosis of OTCD, allow more accurate genetic counseling and can be extended to 
screening regulatory regions of other disease-causing genes. 
Materials and Methods 
Study Subjects  
Subjects selected by Dr. Ljubica Caldovic and Timothy Feeney included three 
patients with reduced or absent OTC enzyme activity and/or urinary orotate above 30 
µmoles/mmoles of urinary creatinine, but no disease-causing mutations in the exons and 
intron/exon boundaries of the OTC gene. Patient 1 was a male diagnosed with late onset 
OTCD based on OTC activity of 6.5 µmoles min-1 g-1, which was approximately one-
tenth of the normal value (56.7 µmoles min-1 per gram of liver tissue). Patient 2 was a 
male diagnosed with late onset OTCD based on OTC activity of 10.3 µmoles min-1 g-1, 
and urinary orotate concentration of 77 µmoles/mmoles creatinine. Patient 3, a male, was 







Identification of Conserved Sequences in the Upstream Regulatory Regions of 
Mammalian OTC genes.  
15kb of conserved sequence upstream of the translational start codon of human, 
chimpanzee, rat, mouse, dog, pig, cow and horse OTC (Table 17) were identified using 
pairwise BLAST2N [245] to identify upstream regulatory regions. Regions of at least 100 
bp that exhibited more than 70% identity were considered to be highly conserved and 
were used for predicting functional roles such as transcription factor binding.  
Identification of Transcription Factor Binding Sites 
Transcription factor binding sites within the promoter, liver specific enhancer 
(LSE) and upstream regulatory element (URE) from each organism were identified using 
Cis-element over-representation (CLOVER) software [146] in conjunction with the 
TRANSFAC Pro Database [147,246]. DNA sequences of the promoter, LSE and URE 
were aligned using CLUSTAL W [148] and predicted transcription factor binding motifs 
were identified within each region of the alignment. Transcription factor binding sites 
were identified based on raw score ranking and conservation of their position in multiple 
sequence alignments. Binding sites that were present in six out of eight species were 




Table 17. Sequences that were used for identification of conserved regions upstream 
of the OTC coding sequence. 
Species Genome Build Sequence Range 
Human GRCh37.p5 NC_00023.10 38196950…38211950 
Chimpanzee Pan_troglodytes-2.1.4 NC_006491 38679212…38694212 
Mouse Build 37.2 NC_000086.6 9514863…9829563 
Rat RGSC v3.4 NC_005120.2 24594496…24609496 
Dog Build 2.1 NC_006621.2 33065945…33080945 
Pig Sscrofa10 NC_010461.3 36498763…36513763 
Cow 5.2 NC_007331.3 65364456…65379456 




Mutation Analysis of the Conserved Regulatory Regions in the Human OTC Gene 
PCR amplification of the promoter, LSE, and URE was conducted by Timothy 
Feeny on the patient’s genomic DNA. Reagent concentration for PCR amplification were 
as follows: 1.25 U of AmpliTaq DNA polymerase (Applied Biosystems Inc., Carlsbad, 
CA, USA), 0.2 mM of each dNTP, 0.2 µM of each primer, 1X GeneAmp PCR buffer 
with 1.5 mM MgCl2 (Applied Biosystems Inc.), and 100 ng of genomic DNA in a final 
volume of 50 µl. The same conditions were used for amplification of all three regions: 4 
min. initial denaturation at 94˚C, followed by 28 cycles of 30 sec. denaturation at 94˚C, 
30 sec. annealing at 62˚C, and 1 min. extension at 72˚C, and a 5 min. final extension at 
72˚C. Amplification products were resolved using 1% agarose gel electrophoresis to 
confirm successful PCR. Unincorporated primers were removed from amplification 
products using ExoSAP-IT (USB, Molecular Biology Reagents and Biochemicals, 
Cleveland, OH, USA) according to manufacturer’s instructions. In addition to the primers 
that were used for amplification of promoter and LSE, primers that anneal in the middle 
of promoter and LSE amplicons were used for sequencing of these two regulatory regions 
(Table 18). Promoter, LSE and URE were sequenced using Big Dye Terminator kit v3.1 
(Applied Biosystems Inc.) according to manufacturer’s instructions.  
SNP Genotyping  
Genotyping was carried out using TaqMan allele discrimination assays from 
Applied Biosystems Inc. according to manufacturer’s instructions. Primers and allele 
specific probes are listed in Table 19. The end point fluorescence readings were 
performed on an ABI 7900HT sequence detection system (SDS v 2.3 software package, 
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Applied Biosystems Inc.). Samples without template added were used as negative 
controls and 100% agreement between duplicate samples were used for quality control.  
DNA-Protein Pull-Down Assay 
The DNA-protein pull-down assay was carried out by Abigail LaBella using the 
method described previously [95] with some modifications. Biotinylated and non-
biotinylated double stranded DNA with wild-type and mutated HNF4 binding sites were 
purchased from Integrated DNA Technologies (Coralville, IA, USA). Resulting probes 
were referred to as pWT, pSNP1 and pSNP2, respectively; their sequences and the 
sequence of non-specific control DNA are listed in Table 20.  
Nuclear extract was prepared from adult mouse livers of C57Bl/6 mice using 
Nuclear Extraction Kit (Origene, Rockville, MD, USA) according to manufacturer’s 
instructions. The protein concentration in the nuclear extract was determined using 
Bradford Assay Dye Concentrate (Bio-Rad, Hercules, CA, USA). Nuclear extract was 
diluted to final protein concentration of 2 mg/ml using PBS containing protease and 
phosphatase inhibitors (Roche, Indianapolis, IN, USA). The nuclear extract was pre-
cleared with streptavidin coupled Dynabeads (Invitrogen, Carlsbad, CA, USA). Pre-
cleared extract was combined with 20 µg of DNA probe and 100 µl of streptavidin beads 
and incubated for 16 hrs. on a rotating shaker at 4˚C. Following incubation, the beads 
were washed, resuspended in 2x Laemmli sample buffer containing 200 mM DTT, and 
boiled to dissociate bound proteins. Eluted proteins were resolved using SDS-PAGE, 
transferred onto nitrocellulose, and probed with the goat anti-HNF-4α primary antibody 
(Abcam, Cambridge, MA, USA) at 1:1000 dilution followed by HRP-conjugated donkey 
secondary antibody at 1:20,000 dilution (Pierce, Rockford, IL, USA). The bands were 
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visualized using Super Signal West Pico Kit (Pierce) according to the manufacturer’s 
instructions. Band intensity (optical density per mm2) was determined using a GS-800 




Table 18. Sequences of primers used to amplify and sequence upstream regulatory 




Size Primer Sequence 
Right 5’-CACCACCACGTCTAGCTAATTTTTGTATTT-3’ 
Promoter 816 bp 
Left 5’-GTTTAACAGGATCCTCAGATTAAACAGCAT-3’ 
Right 5’-CACCAAAAAGTAGAAATGGGCAGAGAAG-3’ 
LSE 998 bp 
Left 5’-TTAACAGATGGTAATGGTAATGGTAGTTTGTC-3’ 
Right 5’-ACCACCACGTCTAGCTAATTTTTGTATTTT-3’ 
URE 544 bp 
Left 5’-ATTTCTAAAAGCTGCATTGTTTAACAGGAT-3’ 










Table 19. Sequence of primers and allele specific probes used for determining 
frequency of SNP1 and SNP2 in general population.  
Primer Name Primer Sequence 
SNP1 F 5’-AGGAAGCTGAAGGGTGATATTACCT-3’ 
SNP1 R 5’-GGCCACCTAAAAACTAAGAAATGTGT-3’ 
SNP1 VIC 5’-TGCAGTGAGGGAGCAA-3’ 
SNP1 FAM 5’-TGCAGTGATGGAGCAA-3’ 
SNP2 F 5’-TGCCCTGCAGTATCTCTAACCA-3’ 
SNP2 R 5’-GGCCACCTAAAAACTAAGAAATGTGT-3’ 
SNP2 VIC 5’-AGGGAGCAAAGGTAATAT-3’ 




Table 20. DNA probes used to determine binding of HNF4 to the wild-type, mutated 











































Regulatory Elements and Transcription Factor Binding Sites in Mammalian OTC 
The urea cycle is essential for disposal of toxic ammonia in mammals, therefore 
we reasoned that cis-acting elements regulating expression of the OTC gene will be 
conserved. Using bioinformatic approaches to establish regions of conservation within 
the 5’-flanking sequence, we identified possible binding sites for transcription factors that 
regulate expression of mammalian OTC. Pair-wise comparisons identified three 
conserved regions upstream of the first exon of OTC (Figure 20). The first region is 571 
bp long and located immediately upstream of the initiating ATG codon. This area 
encompasses the OTC promoter and the 5’-untranslated regions of the OTC mRNA. The 
second region is approximately 900 bp long and corresponds to the -11 kb enhancer in 
the rat Otc gene [51,73]. Because this enhancer is essential for high expression of OTC in 
the liver [73], we termed this cis-acting element the liver specific enhancer (LSE; Figure 
20). The LSE is located between 5 and 11 kb upstream of the OTC promoter in the eight 
examined mammals and it is located approximately 9 kb upstream of the human OTC 
promoter (Figure 20). The third region, located approximately 2 kb upstream of the LSE, 
has not been identified before and we termed this sequence the upstream regulatory 
element (URE) (Figure 20). Figure 20 also shows the conservation track of the 15 kb 
genomic sequence with additional conserved regions between the promoter and the LSE, 
and upstream of the URE. This difference is likely due to different computational 




Figure 20. Conserved elements in mammalian OTC genes.  
Pair-wise BLAST analysis was used to identify three regions of conservation that were 
present in 5’-flanking sequences of all eight mammalian OTC genes. All three regions 
can be identified in the conservation track that displays sequence conservation in 
placental mammals. Red – promoter; green – liver specific enhancer (LSE); blue – 




Promoter, LSE and URE from all eight mammals were then analyzed using 
CLOVER software to identify transcription factor binding sites that may be responsible 
for regulation of the OTC gene. The ability of CLOVER to identify known transcription 
factor binding sites [51,55,73] was used as positive control. Figure 20 shows LOGO 
alignments of the OTC regulatory regions and the predicted transcription factor binding 
sites (magenta) together with the location of cis-acting regulatory elements identified in 
the rat Otc gene (yellow boxes); [51,55,73]. CLOVER correctly predicted binding sites 
for HNF4 and COUP-TF [55] in regions B and C in the OTC promoters of the 
mammalian species (Figure 21A). Binding sites for HNF4 and COUP-TF were predicted 
in region D, while hepatic nuclear factors 3 and 6 (HNF3 and HNF6) were predicted to 
bind to region A (Figure 21A). Although regions A and D have been identified as cis-
acting regulators of OTC expression [51], transcription factors that bind to these two 
regions have not been identified previously. Finally, CLOVER identified conserved 
binding sites for transcription factors Oct-1 and HNF3 upstream of region A (Figure 
21A).  
The region of conservation located approximately 9 kb upstream of the human 
OTC translation initiation codon is approximately 600 bp longer than the experimentally 
identified LSE [51] (Figure 21B). Binding of HNF4 was correctly predicted at sites I and 
IV in the rat [51,73] and the other seven mammals included in this analysis (Figure 21B). 
Two binding sites for C/EBP and one for HNF3 were predicted to reside downstream of 
site IV in all eight species (Figure 21B). However, binding sites for transcription factor 
C/EBP, which binds to sites II and III of the rat LSE [51,73], were not identified. Instead, 
our analysis identified conserved HNF3 and GATA-2 binding sequences in site II and 
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adjacent to site III, respectively (Figure 21B). Within the URE, CLOVER predicted 
binding sites for immunoglobulin transcription factor 4 (TCF-4) and homeobox 
transcription factor Cdx-2 (Figure 21C).  
Mutation Analysis of the OTC Gene Regulatory Regions in Patients with OTCD 
The sequence of the OTC promoter, LSE and URE were screened for mutations in 
the three subjects by Timothy Feeny. Sequencing results were compared to a wild-type 
sequence from an individual without OTCD and to the reference sequence of the human 
genome. Two sequence changes, found in the promoter, were designated SNP1 and SNP2 
(Figure 22). SNP1 and SNP2 are located in region C, where HNF4 binds and activates 
transcription of the rat Otc gene [51,55]. Patients 1 and 2 had SNP1, which is a C to A 
transversion, located 95 bp upstream of the translation initiation codon (Figure 22). SNP1 
is immediately adjacent to the HNF4 binding site, and therefore it could disrupt binding 
of this transcription factor and activation of OTC transcription. Patient 3 had SNP2, a C 
to T transition located 105 bp upstream of the translation initiation codon. This sequence 
change affects a base pair that is highly conserved in HNF4 binding sites [248] and, 

































Figure 21. LOGO representations of sequence alignment of conserved elements 
from 5’-flanking regions of OTC genes from eight mammalian species.  
OTC promoters (A), liver-specific enhancers (B) and upstream regulatory regions (C) 
were aligned using Clustal W and analyzed with CLOVER to identify transcription factor 
binding sites. Experimentally verified transcription factor binding sites are shown in 
cyan. Predicted binding sites are shown in magenta. Yellow boxes indicate regions that 
bind transcription factors within rat Otc promoter and enhancer. Up-arrows indicate 
positions of SNPs in the regulatory regions of the human OTC gene; a previously 




 We queried build 135 of Single Nucleotide Polymorphism Database (dbSNP) to 
determine if the sequence changes may have been identified previously. SNP1 and SNP2 
were not among the 10 polymorphisms identified in the OTC promoter (Figure 22). To 
further exclude the possibility that the sequence changes may be present in the general 
population, we conducted SNP genotyping in 362 healthy individuals at these two 
positions. All tested individuals had wild-type alleles at DNA positions corresponding to 
SNP1 and 2 (Table 21). Tested populations included a diverse cohort of subjects from the 
human genome diversity panel [217] and 256 subjects of Northern European Caucasian 
descent from the FAMUSS study [218]. Assuming equal distribution of genders in both 
test populations, the three sequence changes were absent in 540 alleles, corresponding to 
less than 0.18% frequency of the patients’ A and T alleles for SNP1 and 2, respectively. 




Figure 22. Mutations, polymorphisms, and transcription factor binding sites in the 
human OTC promoter.  
SNP1 and SNP2, identified in this study, are shown in red and underlined typeface. 
Common polymorphisms are shown in bold italic and underlined typeface. Rare 
polymorphisms, identified through 1000 genomes project, are shown in boxed typeface. 
A previously identified mutation in OTC promoter is shown in bold italics typeface. 
Regions A, B, C and D (yellow) correspond to binding sites of transcription factors 
within the rat Otc promoter. Predicted transcription factor binding sites are shown in 
magenta. Binding sites for transcription factors that bind to regions B and C in the rat Otc 
promoter are shown in cyan. Angled arrows indicate transcription starts sites. 
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Table 21. Allele frequencies in populations analyzed by SNP genotyping. 









Number of screened 
individuals. N=362 N=361 
Caucasian 0 188 0 187 
Hispanic 0 13 0 13 
African 
American 0 131 0 137 
Ethnicity 
Unknown 0 30 0 24 
SNP1 NC_000023.10:g.38211844C>A, NG_008471.1:g.5109C>A 




The locations of SNP1 and SNP2 suggest that the mutations could affect binding 
of HNF4 and COUP-TF to their binding site and decrease transcription of the OTC gene. 
DNA pull-down assays, conducted by Abigail LaBella, were used to determine if SNP1 
and SNP2 affect binding of HNF4 to region C of the OTC promoter. Binding of COUP-
TF to region C was not detectable using DNA pull-down assay. Additionally, functional 
studies in cultured cells have shown that region C may not be important for repression of 
OTC transcription by COUP-TF [55]. To isolate the effects of SNP1 and SNP2 on region 
C, wild-type (pWT) and mutated (pSNP1 and pSNP2) probes were used in DNA pull-
down experiments. DNA sequence of similar length located outside OTC promoter and 
non-biotinylated DNA were used as negative controls. The migration of two bands 
(approximately 44 and 52 kDa), indicative of HNF4 binding to pWT, pSNP1 and pSNP2 
(lanes 1, 5 and 7 in Figure 23), were in good agreement with the predicted sizes of two 
HNF4 isoforms, translated from alternatively spliced transcripts [248]. The intensities of 
bands which indicate HNF4 binding to either pSNP1 or pSNP2 were compared to the 
intensity of bands which indicate HNF4 binding to pWT. The bands in lane 5 were 
approximately 37±7% (mean±SEM; n=3) less intense than bands in lane 1 suggesting 
that pSNP1 binds about 40% less HNF4 than pWT (Figure 23). The bands in lane 7 were 
approximately 67±13% (mean±SEM; n=3) less intense than bands in lane 1, similarly 
suggesting that pSNP2 binds less HNF4 than pWT (Figure 23). These data, combined 
with absence of SNP1 and SNP2 in test populations, suggest that these two mutations are 
likely to cause OTCD by reducing binding of HNF4 to the OTC promoter, leading to 




Figure 23. Reduced binding of HNF4 to sites with SNP1 and SNP2 mutations.  
DNA pull-down assays were used to compare binding of HNF4 to its wild type and 
mutated binding sites. Lanes: 1 – biotinylated DNA with wild-type binding site; 2 – 
unlabeled DNA with wild-type binding site; 3 – non-specific biotinylated DNA; 4 – pull-
down without DNA; 5 – biotinylated binding site containing SNP1; 6 – non-biotinylated 
binding site containing SNP1; 7 – biotinylated binding site containing SNP2; 8 – non-

































Herein we report two new mutations in the promoter of the OTC gene and show 
that including the OTC regulatory regions in mutation analysis of the OTC gene will 
likely increase the number of patients with definitive molecular diagnosis of their disease. 
Our bioinformatic analysis of the 5’-flanking regions of eight mammalian OTC genes 
identified the promoter and LSE of the human OTC gene based on similarity to rat Otc 
[196]. A new conserved element located approximately 2 kb upstream of the LSE was 
also identified. CLOVER analysis extended our findings by identifying new potential 
transcription factor binding sites that extend the previously identified conserved regions 
[51,55,73]. 
We used CLOVER software to determine that binding sites for HNF4, COUP-TF 
and C/EBP in the promoter and LSE of rat Otc gene are conserved in other mammals. 
The CLOVER software also predicted binding of HNF3 and HNF6 to region A, and 
binding of HNF4 and COUP-TF to region D of the OTC promoter. Reporter gene assays 
in cultured cells have identified regions A and D as negative and positive cis-regulatory 
elements of the rat Otc gene [51], yet transcription factors that bind and mediate the 
effects of these two regions have not been identified until now. Our analysis also 
identified conserved binding sites for HNF3 and Oct-1 upstream of region A in the OTC 
promoter and HNF3 and C/EBP in the conserved region that extends downstream of the 
four known regulatory sites in the OTC enhancer (Figure 21). Regulation of OTC 
transcription by either HNF3 or GATA-2 has not been shown before. We queried results 
of ENCODE project [183,249] and found that binding of HNF3 and C/EBP transcription 
factors, and p300 transcription co-activator to OTC LSE was detected in HepG2 cells 
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using chromatin immunoprecipitation followed by high throughput sequencing. This 
increased our confidence in the predicted binding of HNF3 to LSE and suggests a role for 
this transcription factor in regulating OTC. 
Mutations in transcription factor binding sites cause disease, including urea cycle 
disorders [95,196]. Up until now, a combination of DNA sequencing and studies of 
decreased transcription factor binding and/or gene function due to a mutation have been 
required to gain acceptance for this kind of causation. In this study, two sequence 
changes were found in the promoter region of three patients with OTCD, and these 
changes were absent in 540 alleles from healthy individuals of diverse ethnic 
background. SNP1 is located immediately adjacent to HNF4 binding site while SNP2 
affects a base pair that is conserved in most HNF4 binding sites [248]. Both sequence 
changes decreased HNF4 binding to the mutated binding sites in vitro (Figure 23). 
Interestingly, although SNP1 and SNP2 decrease HNF4 binding to different extents in 
vitro, their effects on OTC activity in the patients are similar – reduction of OTC activity 
to about 10% of control. We can conclude that reduction in OTC activity is due to 
decreased transcription of the OTC gene, resulting in reduced abundance of OTC mRNA 
and protein. 
Mutations that are not in coding regions or splice junctions, such as these, can 
disrupt any stage in the process of gene expression, from epigenetic regulation, 
transcription, and RNA editing to mRNA stability and translation. Although next 
generation sequencing may become a frequently used diagnostic tool in the near future, a 
method to identify a disease causing sequence change in a timely and cost effective 
manner is lacking. Even with detailed understanding of the roles that cis-acting elements 
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play in gene expression, in vitro studies such as reporter and DNA binding assays may 
not accurately correlate with the severity of disease phenotype in patients. This is well 
illustrated by our experiments with binding of HNF4 to its mutated binding sites. 
Furthermore, functional consequences of sequence changes in introns are even harder to 
test because that would require transformation of cultured cells with artificial 
chromosomes, transgenic animals or even in vivo genome editing. Inspection of 
conservation tracks for the human OTC gene in the UCSC Genome browser revealed 
several putative regulatory regions in introns 1, 2, 3, 4 and 6 that are conserved in 
placental mammals. It is possible that mutations in these regions could cause OTCD but 
their role in expression of OTC must first be established.  
Given the cost and time needed for functional tests of mutated sequences, we 
propose a practical set of steps for diagnosing disease-causing mutations outside of 
coding regions and splice junctions of genes: 1) Combine known information about 
regulation of gene expression with bioinformatic analysis of its sequence including 
conservation of sequences across species, prediction of transcription factor binding sites, 
and sequence variation in the general population; 2) Identify sequence changes in 
patients’ DNA and determine whether they reside in functionally important regions based 
on analysis in step 1; 3) If possible, determine whether patients parents are carriers of 
detected sequence change, and/or whether the mutation segregates with the disease in 
patient’s relatives; 4) Determine frequency of each allele in the population; and 5) Use 
functional tests, if feasible, to show that detected sequence change indeed affects gene 
expression. This framework can be extended to other conserved regions of the OTC gene 
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Chapter 5: Nitrogen load sensing pathways  
Introduction 
The nutrient sensing pathways mTOR, eIF2/GCN2 and AMPK have been shown 
to regulate carbohydrate and fat metabolism [30,31,33,34,250]. Recent studies suggest 
that these pathways also control amino acid metabolism in the liver through changes in 
phosphorylation [23,251,252,253] and may affect changes in the urea cycle enzymes 
through regulation of their trans-acting factors [68,69,74,75,254,255,256]. While studies 
have shown that urea cycle protein expression changes in response to diet [4,5,84], the 
signaling networks that sense and coordinate this response have not been identified. 
Although numerous studies have been conducted to test the effects of nitrogen load on 
individual genes, and recent studies have examined the effects of a carbohydrate only diet 
or fasting on the expression of genes, proteins, and signaling pathways [257], no global 
study, tracking the coordinated changes in gene and protein expression, has been 
conducted using controlled dietary protein.  
Several lines of evidence suggest that AMPK, eIF2 and mTOR may be involved 
in the regulation of ureagenesis. As key nutrient sensors in many cell types 
[30,31,33,34,250], their activity in cultured cells depends on the concentration of amino 
acids, and specifically leucine in the culture medium [23,258,259,260,261]. Therefore, it 
is possible that the branched chain amino acids (BCAA) directly regulate the expression 
of the urea cycle enzymes and urea production mTOR, AMPK and eIF2 signaling. Rats 
fed a high (42%) protein diet exhibited increased phosphorylation of mTOR, while 
phosphorylation of AMPK and eIF2 decreased compared to animals fed a control (12% 
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protein) diet [23]. Similarly, urea cycle enzyme mass and activity have been shown to 
increase upon administration of a high protein diet [3,262]. Along with these data, 
additional evidence to suggest a role for mTOR, AMPK, and eIF2 in regulation of the 
urea cycle genes includes the downstream targets of these pathways. Peroxisome 
proliferator-activated receptor gamma co-activator (PGC-1α)  is activated by the AMPK 
pathway [65,66,67] and then directly regulates the expression of HNF4α (hepatic nuclear 
factor 4 alpha) and the glucocorticoid receptor (GR) [68,69]: transcription factors known 
to control expression of CPS1 and OTC [55,70,71,72,73]. Furthermore, the transcription 
factors CCAAT/element binding protein (C/EBP) and cAMP response element binding 
(CREB) are phosphorylated by AMPK [74,75] and regulate NAGS, CPS1, OTC, ASS, 
and ARG1 [47,63,73,76,77].  
Materials and Methods 
Long Term Feeding Study  
Syngeneic adult male C57BL/6 mice (Jackson Labs) in three groups of 8 were fed 
an isocaloric chow (Harlan Laboratories) with protein content of 10% (low), 20% 
(recommended- control), or 60% (high) ad libitum for 11 days to elicit long-term 
adaptive response to different nitrogen loads. Mice were weighed and their food and 
water consumption was measured each day. On the 12th day, mice were sacrificed and the 
livers were excised and immediately frozen in liquid nitrogen. 
Acute Feeding Study 
Syngeneic adult male C57BL/6 mice were fed isocaloric control (20% protein, 
CP) or high (60% protein, HP) protein diets on a fast/feast cycle consisting of 8 hours 
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fasting, with unlimited access to water, followed by 16 hours of ad libitum feeding for the 
purpose of measurement of RNA and protein levels in response to eating a meal. Mice 
were allowed 11 days to acclimate to this diet and on the 12th day of the study mice were 
sacrificed immediately before scheduled food reintroduction (T0), and at 30 min (T30), 
60 min (T60) and 120 min (T120) after reintroduction of food. Eight mice were included 
at each time point and their livers were collected and immediately frozen in liquid 
nitrogen. 
RNA sample preparation and Microarray Processing  
Hierarchical Clustering Explorer (HCE) 3.5 power analysis tool [263], developed 
at Children’s National Research Center for Genetic Medicine, was used to determine that 
3 replicates would be sufficient to allow for detection of significant differences in mRNA 
levels for 60-80% of probe sets present on each microarray.  
RNA was isolated from frozen liver using TRIzol reagent (Invitrogen) and its 
quality was tested by analyzing RNA concentration through 260/280nm absorbance and 
visualization of 28s and 18s ribosomal bands.  RNA was converted to double-stranded 
cDNA using One-Cycle cDNA Synthesis Kit (Affymetrix) according to manufacturer’s 
instructions, and the cDNA was amplified to ensure greater than 4-fold amplification.  
The cDNA was then transcribed and biotin tagged with the IVT labeling kit (Affymetrix), 
according to manufacturer’s instructions.  The cRNA was purified with the RNAeasy Kit 
(QIAGEN), and fragmented to approximately 200 bp.  To ensure proper fragmentation, 
the IVT fragmented and unfragmented samples were visualized on an agarose gel.  
Following completion of all quality control checks, cRNA was hybridized to GeneChip 
Mouse Genome 430 2.0 (Affymetrix) and the microarray chips were washed and stained 
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on an Affymetrix Fluidics Station 400 within the Center for Genetic Medicine’s 
Expression Profiling core facility, according to manufacturer’s instructions. Fluorescent 
images were scanned using a Hewlett-Packard G2500A Gene Array Scanner [264]. 
Analysis of Transcriptional Profiling Results  
Affymetrix image data was analyzed using Probe Microarray Suite (MAS) 
version 5.0 and dCHIP [265] probe set algorithms to highlight genes both algorithms 
identified as having significant expression level change from the control and to eliminate 
false positives. Genes identified by each algorithm were imported into Partek software 
package (Partek Incorporated), normalized by Log2, and analyzed by 2-way ANOVA 
with p-value of P<0.05. Comparisons for the long-term adaptation study included control 
vs. high, control vs. low, and high vs. low diets. Comparisons for the acute adaptation 
study included control T0 vs high T0, control T30 vs high T30, control T60 vs high T60, 
control T120 vs high 120, control T0 vs control T30, control T0 vs T60, control T0 vs 
control T120, high T0 vs high T30, high T0 vs high T60, and high T0 vs high T120.  
ANOVA results were imported into Ingenuity Pathway Analysis (IPA) software 
(Ingenuity) using Affymetrix probe set IDs as identifiers and absolute fold-change for 
observation values. The long-term adaptation data had expression value cutoffs of -1.7 
and 1.7. The acute adaptation data had expression value cutoffs of -1.5 to 1.5.  
Protein Sample Preparation  
As with transcriptional profiling analysis, HCE 3.5 power analysis tool [263] was 
used to determine that 3 replicas would be sufficient to allow for detection of significant 
differences in liver protein abundance from each of the diets. 
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Total liver protein was extracted from frozen and ground mouse tissue by 
homogenization of tissue in 50 mM Tris-acetate buffer, pH 7.5 containing 250 mM 
sucrose, 1mM EDTA, 1% Nonident P40 (NP40), and Complete Mini Protease Inhibitor 
Cocktail (Roche). Proteins were purified and desalted using Micro Bio-Spin 
Chromatography Columns (Bio-Rad) in Tris buffer. Proteins were then resolved by 
electrophoresis on SDS-PAGE gel, stained, and 1 mm wide sections were excised from 
the gel.  Proteins in the gel were digested using trypsin, and the resulting peptides were 
extracted from the gel using organic solvents. 
Mass Spectrometry and Analysis of Proteomic Profiling Results  
Concentrated peptides from each band were injected via an autosampler (6 uL) 
and loaded onto a Symmetry C18 trap column (5 µm, 300 µm i.d. x 23 mm, Waters) for 
10 min at a flow rate of 10 µL/min, 100% A. The sample was subsequently separated by 
a C18 reverse-phase column (3.5 µm, 75 µm x 15 cm, LC Packings) at a flow rate of 250 
nL/min using an Eksigent nano-hplc system (Dublin, CA). The mobile phases consisted 
of water with 0.1% formic acid (A) and 90% acetonitrile (B). A 65 minute linear gradient 
from 5% to 60% B was employed. Eluted peptides were introduced into the mass 
spectrometer via a 10 µm silica tip (New Objective Inc., Ringoes, NJ) adapted to a nano-
electrospray source (ThermoFisher Scientific). The spray voltage was set at 1.3 kV and 
the heated capillary at 200 °C. The LTQ-Orbitrap-XL (ThermoFisher Scientific) was 
operated in data-dependent mode with dynamic exclusion in which one cycle of 
experiments consisted of a full-MS in the Orbitrap (300-2000 m/z) survey scan and five 
subsequent MS/MS scans in the LTQ of the most intense peaks using collision-induced 
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dissociation with the collision gas (helium) and normalized collision energy value set at 
35%.  
Each file was searched for protein identification using the Sequest algorithm in 
the Bioworks Browser software (ThermoFisher Scientific) against the Uniprot database 
(downloaded June 2009) indexed mouse species and for fully tryptic peptides, 2 missed 
cleavages and no modifications.  DTA generation parameters were Peptide Tolerance of 
50 ppm and Fragment Ion Tolerance of 1 Da. 
Results  
Physiological effects of different feeding regimens on mice 
Mice fed low (10%), control (20%), or high (60%) protein diet did not differ in 
body weight following 12 days of ad libitum (Figure 24A) or time-restricted (Figure 24B) 
feeding. Spontaneous food intake was lower in mice fed the high protein diet (Figure 24C 
and D), most likely due to the satiety signaling to the digestive system following 
consumption of increased dietary protein [266,267]. While urea excretion was not 
measured in this study, the high protein diet most likely results in increased urea 
production as documented previously [268]. Water consumption was increased in mice 
fed the high protein diet (24E and F), presumably to allow for increased urea excretion 
through urination. No significant differences in weight, food intake, or water intake were 
noted in mice on the ad libitum control and low protein diets (Figure 24A, C and E).  
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Figure 24. Weight, food consumption, and water consumption of mice in 12 day 
feeding studies.  
Mice fed an ad libitum diet of low (10%), control (20%) or high (60%) protein (n=8/diet) 
(A) and mice fed on a time-restricted diet of control (20%) or high (60%) protein 
(n=24/diet) (B) showed no difference in weight during 12 days of feeding. Ad libitum fed 
mice on the high protein diet consumed less food (C) and more water (E) than mice on 
the low or control protein diets. High protein fed mice on the time-restricted diet 
consumed less food (D) and more water (F) than mice on the control protein diet. 
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Changes in mRNA expression in mice fed ad libitum 
mRNA was extracted from the livers of mice fed ad libitum high, control, or low 
protein diet for a 12 day period. Microarrays consisting of 45101 probe sets 
corresponding to 21554 unique known genes, were used to determine differences in liver 
mRNA expression. Diet significantly changed (p<0.05) a total of 13771 genes, with the 
greatest difference between the high and low protein diets, 13141 genes. Fewer genes 
significantly differed between the control diet and the low diet, 3926 genes, or high diet, 
5672 genes.  
Hierarchical clustering analysis was carried out on the significant genes in each 
diet group (Figure 26). The replicates of each treatment (n=4) were clustered together, 




Figure 25. Hierarchical clustering of genes from mice fed ad libitum diet of low 
(10%), control (20%) or high (60%) protein.  
mRNA from four mice/diet was collected and assayed for gene expression by microarray. 






Changes in mRNA expression in mice fed a time-restricted diet 
Microarrays were also conducted using mRNA extracted from livers of mice fed a 
high or control diet on a time-restricted 8 and 16 hour fasting-feeding schedule for 12 
days. Livers were collected immediately prior to reintroduction of food, and 30, 60, and 
120 minutes after reintroduction of food on the 12th day. Of the 21554 genes, a total of 
3970 genes differed significantly (p<0.05) by both diet and time. Overall, the time-
restricted feeding schedule led to reduced variability in expression of genes within each 
group as demonstrated by the total number of genes that differed between the high and 
control diet, 7000. This feeding method resulted in many more significantly different 
genes than the ad libitum high and control diets (5672) and subsequent analysis of the 
mRNA expression was based on the time-restricted diet data. 
Within this group of 7000 genes, a greater difference was noted between diets 
than between samples collected at different time points following reintroduction of food. 
Accordingly, hierarchical clustering analysis of significant genes clustered first by diet 
and then by time point (n=3; Figure 26). This clustering was suggested by the number of 
significant genes that differed between diets at a particular time point including 2841 at 0 
min, 3094 at time 30 min, 3982 at time 60 min, and 2590 at time 120 min. In contrast, 
there was a small number of genes whose expression differed between time points within 
a diet (Table 22), suggesting that these changes represent the pace of transcriptional 
activation following feeding. Table 23 shows the top 50 genes that differed between mice 





Figure 26. Hierarchical clustering of genes from mice fed a time-restricted diet of 
control (20%) or high (60%) protein with samples collected immediately before 
reintroduction of food, Time=0, or 30, 60, or 120 minutes after reintroduction of 
food.  
mRNA from three mice/diet/time point was collected and assayed for gene expression by 











Changes in the number of significantly different gene expression (p<0.05) over time, was 
reflected in both the control (20%) and high (60%) protein fed diet groups.  
 
 20% Protein (control) 60% Protein (high) 
T0 vs T30 1132 1141 
T0 vs T60 1515 1405 
T0 vs T120 2454 2307 
 
 133 
Table 23. Top 50 genes that differed between diets and time of collection. 
Gene Symbol Gene Title 
Gldc glycine decarboxylase 
C4bp complement component 4 binding protein 
Antxr2 anthrax toxin receptor 2 
Serpina12 serine (or cysteine) peptidase inhibitor, clade A 
Nat8 N-acetyltransferase 8 (GCN5-related, putative) 
Gm8615 glucosamine-6-phosphate deaminase 1 pseudogene  
Nrp1 neuropilin 1 
Rpl22 ribosomal protein L22 
Orm2 orosomucoid 2 
Gsto1 glutathione S-transferase omega 1 
Eif3e eukaryotic translation initiation factor 3, subunit E 
Ces1e carboxylesterase 1E 
Gpr98 G protein-coupled receptor 98 
Cyp4a31 cytochrome P450, family 4, subfamily a, polypeptide 31 
Nlrp6 NLR family, pyrin domain containing 6 
Ccl9 chemokine (C-C motif) ligand 9 
Tardbp TAR DNA binding protein 
Clec2h C-type lectin domain family 2, member h 
Il1rap interleukin 1 receptor accessory protein 
Dpys dihydropyrimidinase 
Slc13a2 solute carrier family 13  
Dnase2a deoxyribonuclease II alpha 
Ces1d carboxylesterase 1D 
Ikbkg inhibitor of kappaB kinase gamma 
Lbp lipopolysaccharide binding protein 
Rpl10 ribosomal protein 10 
Ldlr low density lipoprotein receptor 
Tardbp TAR DNA binding protein 
Chka choline kinase alpha 
Agxt2l1 alanine-glyoxylate aminotransferase 2-like 1 
Ftl1/Ftl2 ferritin light chain 1 / ferritin light chain 2  
Gabarapl1 gamma-aminobutyric acid A receptor-associated protein-like 1 
Fam55b family with sequence similarity 55, member B 
Tor1a torsin A 
Retsat retinol saturase  
Tnfrsf19 tumor necrosis factor receptor superfamily, member 19 
Nt5e 5' nucleotidase, ecto 
Apol9a / Apol9b apolipoprotein L 9a / b 
Slc22a18 solute carrier family 22  
Ces1d carboxylesterase 1D 
Eef1d eukaryotic translation elongation factor 1 delta  
Suox sulfite oxidase 
Gamt guanidinoacetate methyltransferase 
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Trfr2 transferrin receptor 2 
Agxt alanine-glyoxylate aminotransferase 
1500017E21Rik RIKEN cDNA 1500017E21 gene 
Hmgn2 / Hmgn4 high mobility group nucleosomal binding domain 2 / 4 
Rps3a ribosomal protein S3A 
Eps8l2 EPS8-like 2 




mRNA expression profiling of gene networks and pathways regulated by diet 
mRNA expression profiles and observed expression changes in samples from the 
time-restricted diet study were analyzed to explore metabolic and signaling pathways that 
respond to diet using IPA software. The pathways in which the most genes changed 
expression between diets included lipid metabolism and small molecule biosynthesis, 
which were decreased in mice fed the high protein diet while amino acid metabolism was 
increased in mice fed the high protein diet. In addition, comparison of genes from the 
fasted mice, T0- before reintroduction of food, also identified energy production through 
fatty acid oxidation as the function in which the largest number of genes increased in 
expression in mice fed the control diet. Similarly, the pathway of valine, leucine, and 
isoleucine degradation was up-regulated in the high protein diet reflecting a mechanism 
for maintenance of the body’s nitrogen balance following consumption of a high protein 
meal. In the comparisons between samples collected at different times from mice fed the 
same diet, genes involved in initiation and activation of transcription increased in 
expression 30, 60, and 120 minutes after reintroduction of food, thus reflecting increased 
gene transcription in response to consumption of either diet.  
Changes in protein expression in mice fed ad libitum 
Proteins were isolated from the livers of mice fed ad libitum high, control, or low 
protein diets (n=3) for 12 days, separated using denaturing conditions with SDS-Page 
electrophoresis, extracted using organic solvents, and subject to identification and 
spectral counting using mass spectrometry. A total of about 4000 of the most abundant 
liver proteins were identified using this method and the fold-change of protein expression 
was quantified between diets using spectral counting. Within this group of proteins, 1821 
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unique proteins were identified in all diets. Expression changes were determined using 
fold-change between two diets with cutoffs of ≤ -1.5, for down-regulation, or ≥ 1.5, for 
up-regulation. The liver protein profiles of mice fed the high protein diet showed that 262 
proteins were up-regulated while 569 proteins were down-regulated, compared to mice 
fed the low protein diet. Fewer proteins were up- or down- regulated, 440 and 215 
respectively, when livers of mice fed high protein diets were compared to those fed a 
control diet. Comparison of livers from mice fed the control protein diet to low, identified 
238 up-regulated and 326 down-regulated proteins as well. Table 24 shows the top 50 
proteins that differed between mice on the high and control diets and by time of 
collection. 
Protein expression profiling identifies candidate pathways regulated by diet 
Protein expression data from ad libitum fed mouse samples were analyzed to 
determine pathways that respond to diet using IPA software. Proteins whose expression 
significantly differed between diets were involved in up-regulation of protein synthesis, 
amino acid metabolism, and energy production in response to the high protein diet, and 
involved in up-regulation of lipid metabolism in response to the low protein diet. Within 
these functional groups, eIF2 signaling, valine, leucine, and isoleucine degradation, and 
fatty acid metabolism had the most significant p-values based on the number of genes and 
degree of expression changes. These pathways had greatest number of proteins whose 
expression changed when making comparisons between the low, control, and high 
protein diets.   
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Table 24. Top 50 proteins that differed between diets 
Protein 
Symbol Protein Title 
CPSM Carbamoyl-phosphate synthase [ammonia], mitochondrial  
FAS Fatty acid synthase  
MYH9 Myosin-9  
DYHC1 Cytoplasmic dynein 1 heavy chain 1  
ACLY ATP-citrate synthase  
FTHFD 10-formyltetrahydrofolate dehydrogenase  
ACACA Acetyl-CoA carboxylase 1  
CH60 60 kDa heat shock protein, mitochondrial  
TLN1 Talin-1  
M2GD Dimethylglycine dehydrogenase, mitochondrial  
IQGA2 Ras GTPase-activating-like protein IQGAP2  
PYC Pyruvate carboxylase, mitochondrial  
PYGL Glycogen phosphorylase, liver form  
ATPB ATP synthase subunit beta, mitochondrial  
C1TC C-1-tetrahydrofolate synthase, cytoplasmic  
FLNB Filamin-B  
GRP78 78 kDa glucose-regulated protein  
HSP7C Heat shock cognate 71 kDa protein  
HSP72 Heat shock-related 70 kDa protein 2  
MUG1 Murinoglobulin-1  
CATA Catalase  
AASS Alpha-aminoadipic semialdehyde synthase, mitochondrial  
CLH Clathrin heavy chain 1  
SBP2 Selenium-binding protein 2  
THIM 3-ketoacyl-CoA thiolase, mitochondrial  
ACOX1 Peroxisomal acyl-coenzyme A oxidase 1  
MTP Microsomal triglyceride transfer protein large subunit  
ATPA ATP synthase subunit alpha, mitochondrial  
LPPRC Leucine-rich PPR motif-containing protein, mitochondrial  
ECHA Trifunctional enzyme subunit alpha, mitochondrial  
ENPL Endoplasmin  
ACOC Cytoplasmic aconitate hydratase  
ENOA Alpha-enolase  
HYES Epoxide hydrolase 2  
GRP75 Stress-70 protein, mitochondrial  
IDHC Isocitrate dehydrogenase [NADP] cytoplasmic  
RRBP1 Ribosome-binding protein 1  
SARDH Sarcosine dehydrogenase, mitochondrial  
ACADV Very long-chain specific acyl-CoA dehydrogenase, mitochondrial  
DHE3 Glutamate dehydrogenase 1, mitochondrial  
SND1 Staphylococcal nuclease domain-containing protein 1  




ANXA6 Annexin A6  
ASSY Argininosuccinate synthase  
EF2 Elongation factor 2  
TERA Transitional endoplasmic reticulum ATPase  
PGK1 Phosphoglycerate kinase 1  
SBP1 Selenium-binding protein 1  
ACON Aconitate hydratase, mitochondrial  




Nutrient Sensing pathways are regulated by protein content of diet 
The main focus for these studies was to identify the signaling mechanism that 
senses intake of dietary amino acids. The mRNA expression data revealed that the 
AMPK signaling pathway (change in 13 genes, p-value 6.6×10-3) is up-regulated in 
response to high protein diet while protein expression data revealed that the eIF2 (change 
in 105 proteins, p-value 5.1×10-52) and mTOR (change in 67 proteins, p-value 1.09×10-28) 
signaling pathways are also involved in amino acid sensing, and are up-regulated in 
response to high protein diet. The AMPK, mTOR, and eIF2 pathways share nutrient 
directed messaging, especially by insulin, and each pathway influences the other so that 
they should be considered as a single combined mechanism (Figure 27). Analysis of these 
pathways, which are integral to nutrient sensing and metabolism of fats and 
carbohydrates, identified 16 genes and 19 proteins that change in association with diet 
and time of tissue collection after feeding (Table 25). Within a treatment, the up- or 
down-regulated genes differed by diet and time of tissue collection (Table 25A, Figure 
28A, B, C, and D) and the differentially regulated proteins differ by diet (Table 25B, 




Figure 27. Pathways involved in sensing changes in protein content of diet.  
The AMPK, mTOR, and eIF2 nutrient sensing pathways are integral to carbohydrate and fat metabolism and mRNA and protein 





























































































































































gene name High vs Control protein diets 
 T0 T30 T60 T120 
PI3K     
PP2A      
PP2C      
PDK1      
PKA      
AMPKα      
ACC     
HMGCR     
FASN     
GYS     
TSC1       
GSK3β      
eIF1      
eIF5      
40S ribosomal subunit       
60S ribosomal subunit     
protein name High vs Low High vs. Control Control vs Low 
AMPKγ    
IRS1,2     
PKA    
PP2C    
PI3K     
ACC    
GYS    
FASN    
RPS6     
eIF2γ    
eIF2β     
eIF3    
eIF4A    
eIF4B     
eIF4C    
eIF4E    
eIF4G    
PABP    




Figure 28A. mRNA expression changes in the AMPK, mTOR, and eIF2 pathways by diet.  
Expression of mRNA increased (red) or decreased (green) in mice fed the time-restricted high protein compared to the control protein 







































































































































Figure 28B. mRNA expression changes in the AMPK, mTOR, and eIF2 pathways by diet.  
Expression of mRNA increased (red) or decreased (green) in mice fed the time-restricted high protein compared to the control protein 







































































































































Figure 28C. mRNA expression changes in the AMPK, mTOR, and eIF2 pathways by diet.  
Expression of mRNA increased (red) or decreased (green) in mice fed the time-restricted high protein compared to the control protein 







































































































































Figure 28D. mRNA expression changes in the AMPK, mTOR, and eIF2 pathways by diet.  
Expression of mRNA increased (red) or decreased (green) in mice fed the time-restricted high protein compared to the control protein 








































































































































Figure 29A. Protein expression changes in the AMPK, mTOR, and eIF2 pathways by diet.  
Expression of protein changed by diet in mice fed ad libitum. Protein expression increased (red) or decreased (green) in mice fed the 







































































































































Figure 29B. Protein expression changes in the AMPK, mTOR, and eIF2 pathways by diet.  
Expression of protein changed by diet in mice fed ad libitum. Protein expression increased (red) or decreased (green) in mice fed the 







































































































































Figure 29C. Protein expression changes in the AMPK, mTOR, and eIF2 pathways by diet.  
Expression of protein changed by diet in mice fed ad libitum. Protein expression increased (red) or decreased (green) in mice fed the 






































































































































At the mRNA level (Table 25A, Figure 28), several genes change expression over 
time including phosphatidyinositol-3-kinase (PI3K), protein phosphatase 2A (PP2A), and 
protein phosphatase 2C (PP2C), upstream of the AMPK, mTOR, and eIF2 pathways. In 
mice fed a high protein diet, expression of these genes in increased as demonstrated by 
greater expression in the high protein than the control protein diet by 60 minutes after 
reintroduction of food (Figure 28C). By 120 minutes after reintroduction of food, 
AMPKα and its activators protein kinase A (PKA), PI3K and 3-phosphoinositide 
dependent protein kinase-1 (PDK1) were all up-regulated in the high protein diet group 
(Figure 28D). In further support of the interpretation of the expression results suggesting 
the activation of AMPK in the high protein diet group, acetyl CoA carboxylase (ACC), 
hydroxymethylglutaryl-CoA reductase (HMGCR), glycogen synthase (GYS), and fatty 
acid synthase (FASN), which are all inhibited by AMPK, had decreased expression in the 
high protein diet at all time points (Figure 28A, B, C, and D). Upstream of mTOR, 
protein kinase C (PKC) represses the mTOR inhibiting complex tuberous sclerosis 1 & 2 
(TSC). Expression of TSC1 increased in the high protein diet 30 minutes after 
reintroduction of food (Figure 28B) in accordance with increased mTOR inhibition in the 
high protein diet group. The kinases upstream of eIF2, including PI3K, PDK1, and 
glycogen synthase kinase 3-beta (GSK3β), inhibit eIF2β by phosphorylation and are 
counteracted by insulin. mRNA expression of these kinases is higher in the high protein 
diet than the control diet 120 minutes after reintroduction of food (Figure 28D), reflecting 
the control diet’s abundance of carbohydrates. Downstream, the eukaryotic initiation 
factor (eIF) 5 gene, which mediates release of the translation initiation complex to allow 
for elongation as the final step of eIF2 signaling, has increased expression in mice fed the 
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high protein versus the control diet after 120 minutes (Figure 28D), further suggesting 
that the high protein diet stimulates eIF2 signaling of translation. Overall the mRNA 
expression data indicates increased signaling through AMPK and eIF2 with inhibition of 
mTOR signaling. 
Examination of the protein expression data for differences between high, control 
and low protein diets identified a possible response mechanism to long-term exposure to 
each diet (Table 25B, Figure 29). Expression of PP2C, the AMP sensitive AMPK 
inhibitor, is decreased in the high protein diet while IRS1/2, PI3K, and PKA, which 
activate AMPK in response to insulin and AMP, are increased in the high protein diet 
compared to the control diet (Figure 29A and B). Downstream of AMPK, ACC and 
FASN, proteins inhibited by AMPK, have the highest expression in the low protein diet 
(Figure 29). In the cascade of mTOR phosphorylation, its target 70-kDa ribosomal 
protein S6 kinase (p70S6K) activates eIF4B and phosphorylates ribosomal protein S6 
(RPS6). Both eIF4B and eIF3, which is activated by RPS6, increased in expression in 
association with a high protein diet (Figure 29A). Additional eIF4 translation initiation 
complex members in the mTOR pathway, including eIF4A and eIF4G, have varying 
response to diet such that eIF4A only shows a slight increase following feeding of the 
low protein diet, and eIF4G decreases expression in the high or low protein diets 
compared to the control diet (Figure 29). eIF2β and eIF2γ, members of the eIF2 pathway 
translation initiation complex, increase expression when mice were fed the high or 
protein diet (Figure 29B and C). Further down the eIF2 pathway, members of the 
translation elongation complex eIF2β, eIF2γ, eIF4C, poly(A) binding protein (PABP), 
and eIF5 all have varying response to diet (Figure 29). Overall, the expression of eIF2β 
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and eIF2γ seemed to be decreased in the low protein diet group, eIF3 is increased in the 
high protein diet groups, eIF4C had increased expression in the high and low protein 
groups and PABP and eIF5 had lowest expression in the high protein group (Figure 29). 
These varying results suggest that the high protein diet leads to an inhibition of mTOR 
and eIF2 signaled translation elongation, while it also leads to an increase of eIF2 
translation initiation. 
Changes in urea cycle expression in response to diet 
Expression of the urea cycle genes and enzymes was analyzed and, with the 
exception of NAGS, their response to diet matched the previously reported studies 
[4,5,84] such that their expression of mRNA (Figure 30) and protein (Figure 31) 
increased in a high protein diet and decreased in a low protein diet. NAGS mRNA 
expression, however, decreased in the high protein diet, but, due to very low abundance 
of the NAGS protein, it is undetectable by mass spectrometry. The cause for this 
disparate expression remains unknown. While additional mechanisms may be regulating 
the activity and/or availability of NAGS and all of these enzymes, overall, the urea cycle 
enzymes show marked response to dietary protein which is expected for handling the 





Figure 30. Urea cycle gene expression changes in mice fed a time-restricted diet. 
mRNA expression of urea cycle genes was higher in the high protein diet for CPS1 (B), 
OTC (C), ASS (D), ASL (E), Arg1 (F), ORNT (G) while expression of NAGS (A) was 
decreased in the high protein diet. All points represent an averaged normalized 


























































































































































































































































































































































Figure 31. Urea cycle protein expression changes in mice fed an ad libitum diet. 
Protein expression of urea cycle proteins CPS1 (A), OTC (B), ASS (C), ASL (D), Arg1 
(E), ORNT (F) was highest in the high protein diet. NAGS was not detected in label-free 
mass spectrometry quantification. All points represent averaged normalized spectral 






Discussion and Future Directions 
In this study we examined the effect of dietary protein on and expression of 
mouse liver mRNA and protein. Syngeneic adult male mice were fed a diet of low (10%), 
control (20%) or high (60%) protein on either an ad libitum or a time-restricted feeding 
schedule for 12 days. No significant difference in weight was seen between diet groups 
for either feeding schedule. Mice on the high protein diet, however, consumed less food, 
as high protein signals satiety [266,267], and drank more water to excrete the excess urea 
[268].  
In consideration of the physiological changes associated with dietary protein 
consumption, analysis of mRNA expression using the microarray platform identified 
thousands of genes whose expression significantly differed between diets and time points. 
Hierarchical clustering of probe sets by differing expression uniformly grouped samples 
by diet. Since transcriptional regulation of genes typically occurs on a time scale of 
minutes rather than days [269], it was important to analyze changes in gene expression at 
time points after reintroduction of feed. While replicate samples from each time point did 
not all cluster together, earlier time points of 0 and 30 minutes tended to cluster together, 
possibly reflecting the time lag from ingestion of food to signal transcription while and 
the 120 minute time point replicates consistently clustered together to reflect a fed state. 
Upon further examination, the time-restricted feeding schedule successfully synchronized 
expression of genes that respond to diet and twice the number of genes were identified as 
significantly different between high and control protein diets in the time-restricted diet 
vs. the ad libitum diet.  
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Protein expression may play a more important role than mRNA in the response to 
diet and therefore spectral counting analysis was used to identify and measure abundance 
of liver proteins. A limitation of label-free mass spectrometry for spectral counting and 
identification of peptides is a failure to identify low abundance proteins. Regardless, 
proteins involved in nutrient signaling leading to initiation of translation are abundant in 
the liver, as demonstrated by our analysis. The complementary nature of analysis on both 
mRNA and protein expression is reflected in pathway mapping that identified 
metabolism of fats, carbohydrates, and proteins as main functions of the significantly 
differing genes.  
The main focus of this research was to identify signaling pathways responsive to 
dietary protein. In combination, the mRNA and protein expression analysis identified 
AMPK, mTOR, and eIF2 as the main signaling pathways that respond to diet. It is 
important to note that there are a number of shared members in each of these pathways, 
as shown in Figure 27, that reflect mechanisms for control of transcription, translation 
initiation, and translation elongation. As detailed in the previous section, gene and protein 
expression data suggest that AMPK and eIF2 pathways respond to high protein diet by 
increasing signaling through the pathway and increasing transcription or translation 
initation. mTOR signaling and translation elongation signaling through eIF2, however 
appear to decrease in response to a diet high in protein. It is important to note that within 
a pathway, complexes of proteins that do not respond to diet as a group may either adapt 
without increasing expression of each protein, because the complex can form and 
dissociate fast enough to accommodate the translation initiation and elongation load, or 
may adapt via a post-translational control mechanism such as phosporylation [23].  
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In conclusion, the results of this study strongly suggest that AMPK, mTOR, and 
eIF2 pathways play an important role in responding to dietary protein as they regulate 
translation in response to a high protein diet. The profiling data also show that urea cycle 
genes and enzymes respond to diet and suggests that these nutrient sensing pathways 
have a role in their regulation. To further confirm these analyses, the mRNA expression 
results will be validated using qPCR. qPCR will be performed on genes that change in 
expression due to diet, according to the microarray results, and are involved in the 
nutrient sensing pathways (Table 26). Validation of the mass spectrometry data will be 
conducted by immunoblot and should confirm that urea cycle proteins expression change 
in response to diet via upstream and/or downstream members of the nutrient sensing 
pathways as described in Table 27.  
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Table 26. Genes analyzed for mRNA expression changes using qPCR. 



































Table 27. Proteins analyzed for expression and phosphorylation from mice fed high, 
control or low protein diet  
 mTOR AMPK eIF2 







As an indicator of pathway activity, phosphorylation status of the proteins in 
Table 25 will also be assessed. It is expected that mTOR pathway members will show 
increased phosphorylation following feeding of the high protein diet while AMPK and 
eIF2 pathway members will have reduced phosphorylation [23]. To directly show the 
effect of these pathways on the urea cycle genes mRNA and protein expression, 
additional studies will include targeted inhibition or stimulation of these pathways. Upon 
treatment of primary mouse hepatocytes with rapamycin, it binds the mTOR complex and 
inhibits formation of the mTORC1 complex, thereby inhibiting downstream signaling 
and phosphorylation of p70S6K and 4EBP1 [270,271]. This cascade should decrease 
expression of the urea cycle proteins. 5-aminoimidazole-4-carboxamide-1-beta-4-
ribofuranoside (AICAR) treatment of primary hepatocytes activates AMPK through 5-
amino-4-imidazolecarboxamide ribotide (ZMP) leading to inhibition of AMPK 
dephosphorylation [272,273] and should increase mRNA expression of the urea cycle 
genes. While ACC is used for fatty acid metabolism, and therefore does not directly 
effect the urea cycle, an increase in AMPK activation by AICAR should increase 
phosphorylation and inhibition of ACC. Finally, amino acid sufficiency causes 
phosphorylation of eIF2 by mTORC1 and thereby inhibits its ability to phosphorylate and 
inhibit eIF2α. Therefore, a high protein diet would lead to dephosphorylation of eIF2α 
and increased translation of the urea cycle proteins. Treatment of hepatocytes with 
leucine, the branched chain amino acid commonly thought to signal amino acid load to 
the metabolic machinery [23,274] should trigger the same response in the mTOR, 
AMPK, and eIF2 pathways as a high protein diet and increase mRNA and protein 
expression of the urea cycle enzymes.   
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Chapter 6:  Conclusions and Future Directions 
For this project the overall goal was to identify the mechanism that controls the 
urea cycle’s response to diet. Our approach to answer this question was to first dissect the 
mechanism of transcriptional regulation for NAGS. We learned that NAGS possesses two 
regulatory regions upstream of the translational start site using a combination of 
bioinformatic analyses and in vitro functional assays. We termed these regions the 
promoter and enhancer and used bioinformatic software to identify transcription factor 
binding sites within each region. The possible cis-acting sites were tested and binding 
was verified using chromatin immunoprecipitation, DNA-protein pull-down assays, and 
in vitro functional assays in hepatoma and intestine cell lines. Using 5’ RACE, we found 
that transcription initiates at multiple and different sites in the liver and small intestine, 
and that Sp1 and CREB sites within the promoter facilitate this transcription. The 
enhancer contains binding sites for HNF-1 and NF-Y, and the absence of HNF-1 in 
intestine cells suggests liver specific regulation through the NAGS enhancer. Overall, 
transcription of NAGS is regulated by factors that respond to glucocorticoid and cAMP 
stimulation, as well as through the hepatic nuclear factor (HNF) family of proteins. These 
proteins confer tissue specificity with feedback regulation, and are important for the 
regulation of many urea cycle enzymes.  
Additional future studies could include analysis on differential regulation of 
transcription between the liver and small intestine cells, supported by the 5’RACE results 
and the in vitro liver-specific enhancer. These studies could be used to verify the role of 
NAGS in the small intestine, currently hypothesized to be for citrulline synthesis. To 
further discern the mechanism of transcriptional regulation, studies could investigate the 
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possibility of synergistic activation by the multiple Sp1 sites present, and the importance 
of interactions and feed-back regulation between the HNF factors. Finally, the relatively 
small increase of transcription by the enhancer suggests that another mechanism, perhaps 
a proximal enhancer (Figure 3, promoter B) may also be acting on transcription, and 
additional reporter assays could be conducted to further examine the regulatory regions. 
As a result of the studies on NAGS transcriptional regulation, we were able to 
confirm the diagnosis of NAGS deficiency in a patient with a deleterious mutation in the 
enhancer of NAGS. This patient had the clinical signs of NAGSD, but as initial 
sequencing failed to identify a deleterious mutation she was treated with ammonia 
scavenging agents and a low protein diet for seven years. Clinical trial results showed 
NCG to be markedly effective and, at the same time, a mutation in the HNF-1 binding 
site within the enhancer of NAGS was found to decrease transcriptional activation, as 
tested using in vitro reporter assays, through decreased binding of HNF-1, as determined 
by DNA-protein pull-down assays. Following confirmation by functional studies, she was 
diagnosed with NAGSD, and her treatment was changed to NCG while the drug efficacy 
enabled her to consume protein ad libitum. 
Following the success of the previous study involving NAGSD, a study was 
conducted to analyze the regulatory regions of previously undiagnosed patients with the 
clinical signs of OTC deficiency (OTCD), but lacking deleterious mutations in the exons 
or intron/exon boundries.  Mutations in the promoter of 3 undiagnosed patients were 
determined to be uncommon, using SNP genotyping, and reduced binding of HNF-4 
transcription factor, as determined used DNA-protein pull down assay. Future studies 
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include in vitro functional studies to determine the effect of these mutations on 
transcriptional regulation in hepatocytes.  
The yield of the NAGSD and OTCD regulatory region mutation analysis suggests 
the global importance of this analysis for diagnosis of patients without disease causing 
mutations in the exons and intron/exon boundries, particularly in the advent of exome 
analysis for clinical indications. Ours are only the 2nd and 3rd papers on deleterious 
regulatory region mutations in the urea cycle genes, reflecting the less than 2% of 
currently reported regulatory region mutations in the Human Genome Mutation Database. 
Diagnosing disease caused by non-coding regions variants, however, requires functional 
assays, which are time consuming and impractical for rapid diagnosis. For future 
research, a high throughput method for non-coding region analysis should be developed. 
If and when this comes to be, I would expect the percentage of disease causing mutations 
in the regulatory regions to increase substantially.  
Our research was the first to determine the factors involved in transcriptional 
regulation of NAGS and thereby has enabled further study of the nutrient sensing 
mechanisms that regulate all 6 enzymes in the cycle. Livers from mice in the ad libitum 
feeding study that received the low (10%), control (20%), or high (60%) protein diet and 
the time-restricted diet study that received the control or high protein diets and were 
sacrificed 0, 30, 60 or 120 minutes after reintroduction of food were analyzed for mRNA 
and protein expression using Affymetrix microarray and label-free mass spectrometry 
analysis, respectively. Through these analysis we identified that the AMPK, mTOR, and 
eIF2 nutrient sensing pathways are responsive to content of dietary protein. Our data 
showed an increase in expression of AMPK pathway members, suggesting that it 
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responds to diet by signaling transcription of factors that are known to bind to urea cycle 
enzymes. mTOR and eIF2 pathway members, which are involved in the initiation and 
elongation of translation, show decreased expression in response to the high protein diet, 
and yet urea cycle enzyme protein expression increases. These data will further 
investigated and be validated using qPCR and immunoblotting. 
Future studies for this project could include identification of the amino acid(s) 
that these pathways detect, and we hypothesize that this may involve leucine or 
glutamate. While transcription and protein expression play an important role in 
responding to dietary protein, post-translational modification may provide the mechanism 
for a rapid-response. Additional analyses will include the phosphorylation state of 
AMPK, mTOR, and eIF2 pathway members as well as targeted inhibition or activation of 
the pathways followed by analysis of changes in urea cycle enzyme expression. By 
determining the mechanisms of regulation of the urea cycle, we aim to learn how diet 
affects patients with urea cycle disorders and hope to identify novel treatments based on 
these regulatory mechanisms. In addition, recent studies have demonstrated that 
acetylation could play a role in the regulation of CPS1, OTC and ASL [26,27,28] [264], 
and suggest a role for activation in the remaining urea cycle enzymes as well. Future 
studies could investigate whether this modification is present, which acetylases are 
responsible, and how it affects enzyme activity of urea cycle enzymes. We may find that, 
along with phosphorylation of the nutrient sensing pathways, acetylation is key to 
regulating the rapid response of the urea cycle enzymes to the diet and may provide a 
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